Progress: Procedure completed
Role | Committee | Rapporteur | Shadows |
---|---|---|---|
Lead | ENVI | WÖLKEN Tiemo ( S&D) | COLIN-OESTERLÉ Nathalie ( PPE), KOPCIŃSKA Joanna ( ECR), RIVASI Michèle ( Verts/ALE) |
Former Responsible Committee | ENVI | CABEZÓN RUIZ Soledad ( S&D) | |
Former Committee Opinion | EMPL | ||
Former Committee Opinion | IMCO | BUŞOI Cristian-Silviu ( PPE) | Daniel DALTON ( ECR), Kerstin WESTPHAL ( S&D) |
Former Committee Opinion | JURI | ||
Former Committee Opinion | ECON | ||
Former Committee Opinion | FEMM | ||
Former Committee Opinion | ITRE | WIERINCK Lieve ( ALDE) | |
Former Committee Legal Basis Opinion | JURI | VOSS Axel ( PPE) |
Lead committee dossier:
Legal Basis:
RoP 59-p4, TFEU 114
Legal Basis:
RoP 59-p4, TFEU 114Events
The European Parliament adopted a legislative resolution approving , without amendment, the Council's position at first reading with a view to the adoption of a regulation of the European Parliament and of the Council on health technology assessment and amending Directive 2011/24/EU.
The proposed regulation includes provisions on the use of common methods, procedures and tools for health technology assessment throughout the EU. Health technology assessment (HTA) is an evidence-based scientific process that enables competent authorities to assess the relative effectiveness of new or existing health technologies. HTA focuses in particular on the added value of a health technology compared to other new or existing technologies.
Purpose of the Regulation
The new rules provide for Member States to cooperate in conducting joint clinical assessments and joint scientific consultations . They will also join forces to identify emerging health technologies.
The regulation establishes:
- a support framework and procedures for cooperation between Member States on health technologies at EU level;
- a mechanism whereby all information, analysis and evidence required for the common clinical assessment of health technologies is submitted by the health technology developer only once at EU level ;
- common rules and methods for the common clinical evaluation of health technologies.
Scope and timeframe
Advanced therapy medicinal products would be subject to a joint clinical assessment at the date of application of the regulation, as would medicinal products containing new active substances for the treatment of cancer . In addition, orphan medicinal products and all remaining medicinal products within the scope of the Regulation would be added three and five years respectively after the date of application of the Regulation.
Coordination group
The Member States Coordination Group on Health Technology Assessment will be established.
The Council's position provides for the use of different types of majorities, depending on the type of decisions adopted. The default rule would be that, where consensus cannot be reached, decisions of the Coordination Group would be adopted by simple majority . By way of derogation, a qualified majority would be required for the adoption of the annual work programme and the annual report, as well as for the definition of the strategic direction to be given to the work of the sub-groups.
The Coordination Group will ensure that the joint work carried out is of the highest quality, meets international standards of evidence-based medicine and is timely. It will operate in an independent, impartial and transparent manner.
Completion of the joint clinical evaluation
Upon receipt of the draft common clinical assessment reports and revised summary reports, the coordination group should review them. The coordination group should seek to approve the revised draft reports by consensus. Diverging scientific opinions, including the scientific basis for these opinions, should be included in the reports.
Obligations on Member States
Member States should ‘ give due consideration ’ to the joint clinical assessment reports. A certain number of safeguards were introduced to strengthen obligations on Member States, namely the requirement to annex the joint clinical assessment report to the national health technology assessment and to report on how each joint clinical assessment report was given due consideration in the health technology assessment at national level.
Stakeholder involvement
The Council position states that the subgroups should ensure that patients, clinical experts and other relevant experts participate in the assessment by having the opportunity to provide input on the draft reports. Provisions were also agreed to ensure transparency and absence of conflict of interest during the joint work.
The Committee on the Environment, Public Health and Food Safety adopted the recommendation for second reading contained in the report by Tiemo WÖLKEN (S&D, DE), on the Council's position at first reading with a view to the adoption of a regulation of the European Parliament and of the Council on health technology assessment and amending Directive 2011/24/EU.
The Council's position at first reading reflects the agreement reached between Parliament and the Council in the interinstitutional negotiations at early second reading stage.
As the committee responsible has already confirmed the outcome of these interinstitutional negotiations, it recommends that the plenary confirm the Council's position at first reading, without amendment.
The proposed regulation includes provisions on the use of common methods, procedures and tools for health technology assessment across the EU. It sets out four pillars around which Member States will work together at EU level, namely (1) joint clinical assessments, (2) joint scientific consultations, (3) identification of emerging health technologies, and (4) voluntary cooperation in areas outside the scope of mandatory cooperation.
The main points of the Council's position are as follows:
Scope and timeframe
Advanced therapy medicinal products would be subject to a joint clinical assessment at the date of application of the regulation, as would medicinal products containing new active substances for the treatment of cancer. In addition, orphan medicinal products and all remaining medicinal products within the scope of the Regulation would be added three and five years respectively after the date of application of the Regulation.
Completion of the joint clinical assessment
With regard to the approval of the joint clinical assessment reports by the Coordination Group, the Council's position states that where consensus cannot be reached, the joint assessment should include the diverging scientific opinions and the scientific grounds on which these are based.
Voting regime of the Coordination Group
The Council position provides for the use of different types of majorities, depending on the type of decisions adopted. The default rule would be that, where consensus cannot be reached, decisions of the Coordination Group will be adopted by a simple majority. By way of derogation, a qualified majority would be required for the adoption of the annual work programme and the annual report, as well as for the definition of the strategic direction to be given to the work of the sub-groups.
Obligations on Member States
Member States will be required to “give due consideration” to the joint clinical assessment reports. A certain number of safeguards were introduced to strengthen obligations on Member States, namely the requirement to annex the joint clinical assessment report to the national health technology assessment and to report on how each joint clinical assessment report was given due consideration in the health technology assessment at national level.
Stakeholder involvement
The Council position states that the subgroups should ensure that patients, clinical experts and other relevant experts participate in the assessment by having the opportunity to provide input on the draft reports. Provisions were also agreed to ensure transparency and absence of conflict of interest during the joint work.
The European Parliament adopted a resolution on the proposal for a Regulation of the European Parliament and of the Council on health technology assessment and amending Directive 2011/24/EU.
Parliament’s position adopted at first reading under the ordinary legislative procedure amended the Commission proposal as follows:
The proposed Regulation shall define a support framework and procedures for cooperation on clinical assessment of health technologies at Union level and common methodologies for the clinical assessment of health technologies. Pricing and reimbursement of medicines shall fall within the exclusive national competence of the Member States.
The amended text stipulated that HTA shall be used to promote innovations that produce the best results for patients and society in general. It should enable health professionals, patients and health institutions to know whether or not a new health technology represents an improvement on existing health technologies, in terms of benefits and risks
Independence and transparency
Cooperation should be based on the principle of good governance, which encompasses transparency, objectivity, independent experience and fair procedures. Members insisted that trust is a precondition for successful cooperation.
A coordination group composed of representatives from Member States' health technology assessment authorities and bodies should be established with responsibility and proven expertise for overseeing the carrying out of joint clinical assessments and other joint work within the scope of this Regulation.
In order to ensure high quality of work, members of the Coordination Group shall be drawn from national or regional health technology assessment agencies or bodies responsible for that field. Members serving in the Coordination Group, and experts and assessors in general, shall not have financial interests in any type of health technology developer industry or insurance company that may affect their impartiality. They shall undertake to act independently and in the public interest and shall make an annual declaration of interests. In the event of a conflict of interest, they shall withdraw from the meeting whilst the relevant agenda items are being discussed.
The coordination group shall ensure that relevant stakeholders and experts are consulted in its work.
In addition, in order to ensure transparency and public awareness of the process and to promote confidence in the system, all clinical data being evaluated shall have the highest level of transparency and public communication. Where data is confidential for commercial reasons, its confidentiality shall be clearly defined and justified and the confidential data shall be well delimitated and protected.
Parliament stressed the need to ensure a dialogue between the coordination group and patient organisations, consumer organisations, non-governmental health organisations, experts and health professionals, in particular through a stakeholder network, whose independence, transparency and impartiality of decisions would be guaranteed.
Joint clinical assessment report
The report shall be accompanied by a summary report, which shall contain at least the clinical data compared, the end-points, the comparators, the methodology, the clinical evidence used, and conclusions as regards efficacy, safety, and relative efficacy, the limits of the assessment, diverging views, a summary of the consultations carried out, and the observations made.
The report should be accompanied by a summary report including at least the following elements: (i) comparative clinical data, (ii) efficacy criteria, (iii) efficacy criteria, (iii) comparators, (iv) method, (iii) clinical data used, (iv) conclusions on effectiveness and safety, relative efficacy and evaluation limitations, (v) divergent positions, (vi) summary of consultations carried out and comments received.
The conclusions of the joint clinical assessment report shall include:
- an analysis of the relative effectiveness and safety of the health technology being assessed in terms of the clinical end-points relevant to the clinical entity and patient group chosen for the assessment, including mortality, morbidity and quality of life;
- the degree of certainty of relative effects based on the best available clinical data and compared to the best standard therapies.
Avoid duplication
In order for harmonised procedures to achieve their objective of the internal market and improving innovation and the quality of clinical evidence, Member States shall take account of the results of joint clinical assessments and not repeat them.
However, the amended text stated that according to national needs, Member States shall have the right to complement the joint clinical assessments with additional clinical evidence and analyses to account for differences in comparators or the national specific treatment setting. Such complementary clinical assessments shall be duly justified and proportionate and shall be notified to the Commission and the Coordination Group.
Financing
In order to ensure the availability of sufficient resources for joint work and stable administrative support provided for in the Regulation, the Union shall ensure stable and permanent public funding, as provided for in the multiannual financial framework, for joint work and voluntary cooperation, as well as for the support framework for these activities. Member States shall also have the possibility to second national experts to the Commission in order to support the secretariat of the coordination group.
The European Parliament adopted, by 576 votes to 56 with 41 abstentions, amendments to the proposal for a Regulation of the European Parliament and of the Council on health technology assessment and amending Directive 2011/24/EU.
The matter was referred to the committee for interinstitutional negotiations.
The main amendments to the Commission proposal adopted in plenary session concern the following points:
Purpose : the proposed Regulation shall define a support framework and procedures for cooperation on clinical assessment of health technologies at Union level and common methodologies for the clinical assessment of health technologies. Pricing and reimbursement of medicines shall fall within the exclusive national competence of the Member States.
Cooperation in the field of health technology assessment (HTA) : Members considered that the cooperation between HTA authorities shall be based on the principle of good governance , objectivity, independence and transparency. They stressed that trust is a precondition for successful cooperation.
The amended text stipulated that HTA shall be used to promote innovations that produce the best results for patients and society in general . It should enable health professionals, patients and health institutions to know whether or not a new health technology represents an improvement on existing health technologies, in terms of benefits and risks.
Members therefore considered that joint clinical assessments should therefore aim to identify the added therapeutic value of new or existing health technologies in comparison with other new or existing health technologies, by undertaking a comparative assessment based on comparative trials.
Cooperation shall, inter alia :
promote high-quality innovation , steering research towards addressing the unmet diagnostic, therapeutic or procedural needs of healthcare systems as well as steering clinical and social priorities; improve scientific evidence used to inform clinical decision-making, efficiency in use of resources, the sustainability of health systems, patient access to these health technologies, and the competitiveness of the sector through greater predictability and more efficient research; ensure that Member States use the outcome of HTA to augment the scientific evidence that informs decisions to introduce health technologies into their systems; play a role throughout the health technology cycle ; help in decision-making on divestment in cases where a technology becomes obsolete; contribute to improving and harmonising standards of care as well as diagnostic and new-born screening practices across the Union; cover areas such as diagnostics used to supplement treatment, surgical procedures, prevention, screening and health promotion programmes, information and communications technology (ICT) tools.
In the absence of a commonly agreed definition of what constitutes a high-quality innovation or therapeutic added value, Members called for such definitions to be adopted at EU level.
Avoid duplication : in order for harmonised procedures to achieve their objective of the internal market and improving innovation and the quality of clinical evidence, Member States shall take account of the results of joint clinical assessments and not repeat them.
However, the amended text stated that according to national needs, Member States shall have the right to complement the joint clinical assessments with additional clinical evidence and analyses to account for differences in comparators or the national specific treatment setting. Such complementary clinical assessments shall be duly justified and proportionate and shall be notified to the Commission and the Coordination Group.
Independence and transparency : a coordination group composed of representatives from Member States' health technology assessment authorities and bodies should be established with responsibility and proven expertise for overseeing the carrying out of joint clinical assessments and other joint work within the scope of this Regulation.
In order to ensure high quality of work, members of the Coordination Group shall be drawn from national or regional health technology assessment agencies or bodies responsible for that field. Members serving in the Coordination Group, and experts and assessors in general, shall not have financial interests in any type of health technology developer industry or insurance company that may affect their impartiality. They shall undertake to act independently and in the public interest and shall make an annual declaration of interests. In the event of a conflict of interest, they shall withdraw from the meeting whilst the relevant agenda items are being discussed.
The coordination group shall ensure that relevant stakeholders and experts are consulted in its work.
In addition, in order to ensure transparency and public awareness of the process and to promote confidence in the system, all clinical data being evaluated shall have the highest level of transparency and public communication . Where data is confidential for commercial reasons, its confidentiality shall be clearly defined and justified and the confidential data shall be well delimitated and protected.
Membersstressed the need to ensure a dialogue between the coordination group and patient organisations, consumer organisations, non-governmental health organisations, experts and health professionals, in particular through a stakeholder network , whose independence, transparency and impartiality of decisions would be guaranteed.
Financing : in order to ensure the availability of sufficient resources for joint work and stable administrative support provided for in the Regulation, the Union shall ensure stable and permanent public funding , as provided for in the multiannual financial framework, for joint work and voluntary cooperation, as well as for the support framework for these activities. Member States shall also have the possibility to second national experts to the Commission in order to support the secretariat of the coordination group.
The Committee on the Environment, Public Health and Food Safety adopted the report by Soledad CABEZÓN RUIZ (S&D, ES) on the proposal for a regulation of the European Parliament and of the Council on health technology assessment and amending Directive 2011/24/EU.
The committee recommended that the European Parliament's position adopted at first reading under the ordinary legislative procedure should amend the Commission's proposal as follows.
Purpose : the proposed Regulation shall define a support framework and procedures for cooperation on clinical assessment of health technologies at Union level and common methodologies for the clinical assessment of health technologies. It shall not interfere with the exclusive national competence of Member States for national pricing or reimbursement decisions.
Cooperation in the field of health technology assessment (HTA) : Members considered that the cooperation between HTA authorities shall be based on the principle of good governance , objectivity, independence and transparency. They stressed that trust is a p recondition for successful cooperation.
HTA shall be used to promote innovations that produce the best results for patients and society in general . Health professionals, patients and health institutions need to know whether or not a new health technology represents an improvement on existing health technologies, in terms of benefits and risks. Members therefore considered that joint clinical assessments should therefore aim to identify the added therapeutic value of new or existing health technologies in comparison with other new or existing health technologies, by undertaking a comparative assessment based on comparative trials.
Cooperation shall, inter alia :
promote high-quality innovation , steering research towards addressing the unmet diagnostic, therapeutic or procedural needs of healthcare systems as well as steering clinical and social priorities; improve scientific evidence used to inform clinical decision-making, efficiency in use of resources, the sustainability of health systems, patient access to these health technologies, and the competitiveness of the sector through greater predictability and more efficient research; ensure that Member States use the outcome of HTA to augment the scientific evidence that informs decisions to introduce health technologies into their systems; play a role throughout the health technology cycle ; help in decision-making on divestment in cases where a technology becomes obsolete; contribute to improving and harmonising standards of care as well as diagnostic and new-born screening practices across the Union; cover areas such as diagnostics used to supplement treatment, surgical procedures, prevention, screening and health promotion programmes, information and communications technology (ICT) tools.
Avoid duplication : in order for harmonised procedures to achieve their objective of the internal market and improving innovation and the quality of clinical evidence, Member States shall take account of the results of joint clinical assessments and not repeat them.
However, according to national needs, Member States shall have the right to complement the joint clinical assessments with additional clinical evidence and analyses to account for differences in comparators or the national specific treatment setting. Such complementary clinical assessments shall be duly justified and proportionate and shall be notified to the Commission and the Coordination Group.
Transparency : in order to ensure high quality of work, members of the Coordination Group shall be drawn from national or regional health technology assessment agencies or bodies responsible for that field. Members serving in the Coordination Group, and experts and assessors in general, shall not have financial interests in any type of health technology developer industry or insurance company that may affect their impartiality. They shall undertake to act independently and in the public interest and shall make an annual declaration of interests. In the event of a conflict of interest , they shall withdraw from the meeting whilst the relevant agenda items are being discussed.
In addition, in order to ensure transparency and public awareness of the process and to promote confidence in the system, all clinical data being evaluated shall have the highest level of transparency and public communication. Where data is confidential for commercial reasons, its confidentiality shall be clearly defined and justified and the confidential data shall be well delimitated and protected.
Financing : in order to ensure the availability of sufficient resources for joint work and stable administrative support provided for in the Regulation, the Union shall ensure stable and permanent public funding , as provided for in the multiannual financial framework, for joint work and voluntary cooperation, as well as for the support framework for these activities. Member States shall also have the possibility to second national experts to the Commission in order to support the secretariat of the coordination group.
PURPOSE: foster cooperation between EU Member States in health technology assessment.
PROPOSED ACT: Regulation of the European Parliament and of the Council.
ROLE OF THE EUROPEAN PARLIAMENT: Parliament decides in accordance with the ordinary legislative procedure on an equal footing with Council.
BACKGROUND: health technology assessment (HTA) is a multidisciplinary process (covering medical, social, economic and ethical issues) and an evidence-based process that independently and objectively assesses a new or existing technology and compares it with other health technologies and / or the current standard of care.
Following the adoption of the Cross-Border Healthcare Directive ( Directive 2011/24/EU ), a voluntary European network of HTAs composed of national HTA agencies or bodies was set up (in 2013) to provide strategic and political guidance to the scientific and technical cooperation at Union-level.
While Member States have carried out some joint assessments within the framework of the EU co-funded joint actions, the production of output has been inefficient . Use of the results of the joint actions, including their joint clinical assessments, at Member State-level has remained low. The duplication of assessments on the same health technology by HTA authorities and bodies in different Member States within identical or similar timeframes has not been sufficiently addressed.
The European Parliament, in its resolution of 2 March 2017 called on the Commission to propose legislation on a European system for health technology assessment and to harmonise transparent health technology assessment criteria in order to assess the added therapeutic value of medicines.
IMPACT ASSESSMENT: four policy options were analysed. The preferred option is based on Option 4 ( permanent cooperation on common tools, procedures, early dialogues and joint clinical assessments ), integrating certain elements of Option 2 (project-based cooperation on HTA activities) as well as some adjustments (e.g. transitional arrangements for Member States and progressive implementation of the product scope for joint clinical assessments).
CONTENT: the proposed regulation aims to provide the basis for permanent and sustainable cooperation at the EU level for joint clinical assessments of new medicines and certain new medical devices. Its general objectives are to ensure a better functioning of the internal market and to contribute to a high level of protection of human health. The specific objectives are to improve the availability of innovative health technologies for EU patients, to ensure an efficient use of resources and to improve the quality of HTA across th EU, and to improve business predictability.
Member States will be able to use common HTA tools, methodologies and procedures across the EU, working together in four main areas:
1) Joint clinical assessments: these focus on the most innovative health technologies with the most Union-wide and public health impact. These assessments are limited to:
medicinal products undergoing the central marketing authorisation procedure, new active substances and existing products for which the marketing authorisation is extended to a new therapeutic indication; and certain classes of medical devices and in vitro diagnostic medical devices which have been selected by the Coordination Group set up under the Regulation.
Following the end of a transitional period , participation in the assessments and use of the joint clinical assessment reports at Member State level will be mandatory. Member States will continue to carry out non-clinical assessments (e.g. economic, organisational, ethical) of health technologies and make decisions on pricing and reimbursement.
2) Joint scientific consultations : these allow a developer in the development phase of a health technology to seek the advice of HTA authorities and bodies on the data and evidence likely to be required as part of a potential future joint clinical assessment.
3) Identification of emerging health technologies : This exercise will act as a key input for the annual work programmes, helping to identify at an early stage of their development, the health technologies expected to have a major impact on patients. The Coordination Group will fully consult with all relevant interest groups during this exercise.
4) Voluntary cooperation in other areas : this cooperation could include the assessment of health technologies other than medicinal products or medical devices, non-clinical assessments or collaborative assessments of medical devices not subject to common clinical assessments.
Lastly, the proposal lays down common implementing rules in order to ensure harmonisation of the way in which Member States carry out clinical assessments. A key objective of these rules will be to ensure that clinical assessments, whether at EU or at Member State level, are carried out in an independent and transparent manner, free from conflicts of interests.
BUDGETARY IMPLICATIONS: the implementation of the proposal has no impact on the current Multiannual Financial Framework 2014-2020 as the current cooperation on HTA is financed by the Public Health Programme. The financial impact on the EU budget post-2020 will be part of the Commission's proposals for the next Multiannual Financial Framework.
DELEGATED ACTS: the proposal contains provisions empowering the Commission to adopt delegated acts in accordance with Article 290 of the Treaty on the Functioning of the European Union.
Documents
- Final act published in Official Journal: Regulation 2021/2282
- Final act published in Official Journal: OJ L 458 22.12.2021, p. 0001
- Draft final act: 00080/2021/LEX
- Debate in Parliament: Debate in Parliament
- Decision by Parliament, 2nd reading: T9-0484/2021
- Committee recommendation tabled for plenary, 2nd reading: A9-0334/2021
- Council position: 10531/3/2021
- Council position published: 10531/3/2021
- Commission communication on Council's position: COM(2021)0696
- Commission communication on Council's position: EUR-Lex
- Committee draft report: PE699.301
- Committee letter confirming interinstitutional agreement: PE696.384
- Approval in committee of the text agreed at early 2nd reading interinstitutional negotiations: PE696.384
- Contribution: COM(2018)0051
- Commission response to text adopted in plenary: SP(2019)354
- Decision by Parliament, 1st reading: T8-0120/2019
- Debate in Parliament: Debate in Parliament
- Results of vote in Parliament: Results of vote in Parliament
- Decision by Parliament, 1st reading: T8-0369/2018
- Debate in Parliament: Debate in Parliament
- Committee report tabled for plenary, 1st reading: A8-0289/2018
- Committee opinion: PE620.890
- Specific opinion: PE627.727
- Committee opinion: PE622.139
- Amendments tabled in committee: PE623.757
- Amendments tabled in committee: PE623.758
- Committee draft report: PE622.011
- Contribution: COM(2018)0051
- Contribution: COM(2018)0051
- Contribution: COM(2018)0051
- Contribution: COM(2018)0051
- Document attached to the procedure: EUR-Lex
- Document attached to the procedure: SWD(2018)0041
- Document attached to the procedure: EUR-Lex
- Document attached to the procedure: SWD(2018)0042
- Legislative proposal published: COM(2018)0051
- Legislative proposal published: EUR-Lex
- Document attached to the procedure: EUR-Lex SWD(2018)0041
- Document attached to the procedure: EUR-Lex SWD(2018)0042
- Committee draft report: PE622.011
- Amendments tabled in committee: PE623.757
- Amendments tabled in committee: PE623.758
- Committee opinion: PE622.139
- Specific opinion: PE627.727
- Committee opinion: PE620.890
- Commission response to text adopted in plenary: SP(2019)354
- Committee letter confirming interinstitutional agreement: PE696.384
- Committee draft report: PE699.301
- Commission communication on Council's position: COM(2021)0696 EUR-Lex
- Council position: 10531/3/2021
- Draft final act: 00080/2021/LEX
- Contribution: COM(2018)0051
- Contribution: COM(2018)0051
- Contribution: COM(2018)0051
- Contribution: COM(2018)0051
- Contribution: COM(2018)0051
Activities
- Soledad CABEZÓN RUIZ
Plenary Speeches (4)
- José Inácio FARIA
Plenary Speeches (3)
- Notis MARIAS
Plenary Speeches (3)
- Nicola CAPUTO
Plenary Speeches (2)
- 2016/11/22 Health technology assessment (debate) IT
- 2016/11/22 Health technology assessment (debate) IT
- Françoise GROSSETÊTE
Plenary Speeches (2)
- 2016/11/22 Health technology assessment (debate) FR
- 2016/11/22 Health technology assessment (debate) FR
- Karin KADENBACH
Plenary Speeches (2)
- 2016/11/22 Health technology assessment (debate) DE
- 2016/11/22 Health technology assessment (debate) DE
- Ioan Mircea PAŞCU
Plenary Speeches (2)
- 2016/11/22 Health technology assessment (debate) RO
- 2016/11/22 Health technology assessment (debate) RO
- Christos STYLIANIDES
Plenary Speeches (2)
- 2016/11/22 Health technology assessment (debate)
- 2016/11/22 Health technology assessment (debate)
- Lieve WIERINCK
Plenary Speeches (2)
- 2016/11/22 Health technology assessment (debate) NL
- 2016/11/22 Health technology assessment (debate) NL
- Zoltán BALCZÓ
Plenary Speeches (1)
- Mireille D'ORNANO
Plenary Speeches (1)
- 2016/11/22 Health technology assessment (debate) FR
- Georgios EPITIDEIOS
Plenary Speeches (1)
- 2016/11/22 Health technology assessment (debate) EL
- Elena GENTILE
Plenary Speeches (1)
- 2016/11/22 Health technology assessment (debate) IT
- Ivan JAKOVČIĆ
Plenary Speeches (1)
- 2016/11/22 Health technology assessment (debate) HR
- Gesine MEISSNER
Plenary Speeches (1)
- 2016/11/22 Health technology assessment (debate) DE
- Bolesław G. PIECHA
Plenary Speeches (1)
- 2016/11/22 Health technology assessment (debate) PL
- Eleftherios SYNADINOS
Plenary Speeches (1)
- 2016/11/22 Health technology assessment (debate) EL
- Adam SZEJNFELD
Plenary Speeches (1)
- Claudiu Ciprian TĂNĂSESCU
Plenary Speeches (1)
- 2016/11/22 Health technology assessment (debate) RO
Votes
A8-0289/2018 - Soledad Cabezón Ruiz - Am 209 03/10/2018 12:39:29.000 #
A8-0289/2018 - Soledad Cabezón Ruiz - Proposition de la Commission 03/10/2018 12:44:23.000 #
Amendments | Dossier |
697 |
2018/0018(COD)
2018/05/25
ITRE
126 amendments...
Amendment 100 #
Proposal for a regulation Article 10 – paragraph 1 – point a – point ii (ii) select medicinal products referred to in Article 5(1)(a) for joint clinical assessment based on the
Amendment 101 #
Proposal for a regulation Article 10.º – paragraph 1 – point b – point ii Amendment 102 #
Proposal for a regulation Article 11 – paragraph 1 – introductory part 1. The Co
Amendment 103 #
Proposal for a regulation Article 11 – paragraph 1 – point a (a) submissions of information, data and evidence by health technology developers including the protection of developers' confidential information;
Amendment 104 #
Proposal for a regulation Article 11 – paragraph 1 – point a a (new) (a a) The application of the selection criteria referred to in Article 10 (a) (ii)
Amendment 105 #
Proposal for a regulation Article 11 – paragraph 2 Amendment 106 #
Proposal for a regulation Article 12 – paragraph 3 a (new) 3 a. For medicinal products, Article 12 (2) and 12 (3) shall not apply.
Amendment 107 #
Proposal for a regulation Article 13 – paragraph 8 8. The designated sub-group shall ensure that stakeholders, including patients, consumers and clinical experts are given an opportunity to provide comments during the preparation of the draft joint scientific consultation report and set a time-frame in which they may submit comments.
Amendment 108 #
Proposal for a regulation Article 13 – paragraph 12 12. The Coordination Group shall approve the final joint scientific consultation report, wherever possible by consensus or, where necessary, by a
Amendment 109 #
Proposal for a regulation Article 13 – paragraph 12 a (new) 12 a. Delegates participating in the elaboration of joint scientific consultations for a health technology may not participate in the joint clinical assessment of this particular technology.
Amendment 110 #
Proposal for a regulation Article 14 – paragraph 2 2. The Coordination Group shall include
Amendment 111 #
Proposal for a regulation Article 14 – paragraph 2 2. The Coordination Group shall include anonymised summary information on the joint scientific consultations in its annual reports and the IT platform referred to in Article 27. The scientific consultation reports shall be made public once the joint clinical assessments have been completed.
Amendment 112 #
Proposal for a regulation Article 16 – paragraph 1 – introductory part 1. The Co
Amendment 113 #
Proposal for a regulation Article 16 – paragraph 1 – point d (d) the consultation of patients, health professionals, clinical experts and other relevant stakeholders;
Amendment 114 #
Proposal for a regulation Article 16 – paragraph 1 – point d (d) the consultation of patients, consumers, clinical experts and other relevant stakeholders;
Amendment 115 #
Proposal for a regulation Article 17 – paragraph 1 – introductory part The Co
Amendment 116 #
Proposal for a regulation Article 17 – paragraph 1 – point b (b) the rules for determining the stakeholders to be consulted for the purpose of this Section. Declarations on conflicts of interest must be publicly available for all stakeholder and experts with conflict of interests shall not participate in the process.
Amendment 117 #
Proposal for a regulation Article 18 – paragraph 1 1. The Coordination Group shall annually prepare a study on emerging health technologies expected to have a major impact on patients, public health or healthcare systems. Following the end of the transitional period referred to in Article 33(1), with respect to medicinal products, the identification of emerging health technologies shall follow the EMA pre-notification of medicinal products prior to marketing authorization applications.
Amendment 118 #
Proposal for a regulation Article 18 – paragraph 2 – point b (b) patient and consumer organisations;
Amendment 119 #
Proposal for a regulation Article 18 – paragraph 2 – point c a (new) (c a) Health professionals
Amendment 120 #
Proposal for a regulation Article 19 – paragraph 1 – point d (d) the provision of additional evidence necessary to support health technology assessments, including computer modeling and simulation data.
Amendment 121 #
Proposal for a regulation Article 19 – paragraph 3 3. The cooperation referred to in paragraph 1 points (b) and (c) may be carried out using the procedural rules established
Amendment 122 #
Proposal for a regulation Article 20 – paragraph 1 – introductory part The common procedural rules and methodology established
Amendment 123 #
Proposal for a regulation Article 22 – paragraph 1 – introductory part 1. The Co
Amendment 124 #
Proposal for a regulation Article 22 – paragraph 1 – introductory part 1. The Commission shall adopt
Amendment 125 #
Proposal for a regulation Article 22 – paragraph 1 – point a – point ii (ii) the mechanisms for the interaction between health technology bodies and health technology developers during clinical assessments including as regards to the protection of developer's confidential information;
Amendment 126 #
Proposal for a regulation Article 22 – paragraph 1 – point a – point iii (iii) the consultation of patients, consumers, clinical experts, and other stakeholders in clinical assessments. The declarations of conflicts of interest of consulted shareholders must be publicly available.
Amendment 127 #
Proposal for a regulation Article 22 – paragraph 1 – point b (b) methodologies used to formulate the contents and design of clinical assessments, based on the common tools and methodologies for cooperation developed after many years of cooperation through EUnetHTA Joint Actions, BeNeLuxA and Valletta.
Amendment 128 #
Proposal for a regulation Article 22 – paragraph 1 a (new) 1 a. The methodologies referred to in paragraph 1(b) shall be developed on the basis of the existing EUnetHTA methodological guidelines and evidence submission templates. They shall be developed and agreed after consultations with all stakeholders, in a transparent manner, regularly updated to reflect the evolution of science and publicly available.
Amendment 129 #
Proposal for a regulation Article 22 – paragraph 1 b (new) Amendment 130 #
Proposal for a regulation Article 22 – paragraph 1 c (new) 1 c. The methodology shall also: a) Provide for a suitable mechanism to create consensus on the identification of the patient-relevant health outcome, taking due account of the roles and preferences of relevant stakeholders, including patients, physicians, regulators, HTA bodies and health technology developers; b) take into account potential changes relating to the relevant comparator at national level due to the rapidly evolving standards of care.
Amendment 131 #
Proposal for a regulation Article 22 – paragraph 2 Amendment 132 #
Proposal for a regulation Article 23 – paragraph 1 – introductory part The Co
Amendment 133 #
Proposal for a regulation Article 23 – paragraph 1 a (new) 2. The data and evidence referred in paragraph 1(a)(i) shall be limited to the best available evidence at the time of the submission for clinical assessment and may include data from other sources than randomized clinical trials.
Amendment 134 #
Proposal for a regulation Article 24 – paragraph 2 a (new) 2 a. In any event, the Union shall ensure stable and permanent public funding under the Multiannual Financial Framework.
Amendment 135 #
Proposal for a regulation Article 25 – paragraph 1 – point e (e) facilitate cooperation with the European Medicines Agency on the joint work on medicinal products including the sharing of confidential information; The sharing of confidential information needs to be proportionate to and aligned with the requirements for the joint clinical assessments and be discussed and agreed by the health technology developer or other relevant stakeholders;
Amendment 136 #
Proposal for a regulation Article 26 – paragraph 1 1. The Commission shall establish a stakeholder network through an open call for applications and a selection of suitable stakeholder organisations based on selection criteria established in the open call for applications. The Commission services shall take the following criteria into account when assessing applications:
Amendment 137 #
Proposal for a regulation Article 26 – paragraph 1 – point i (new) (i) demonstrated current or planned engagement in HTA development (activity reports, work plans, position papers, active working groups, EU-funded actions);
Amendment 138 #
Proposal for a regulation Article 26 – paragraph 1 – point ii (new) (ii) professional expertise relevant to the aims of the Pool at EU level;
Amendment 139 #
Proposal for a regulation Article 26 – paragraph 1 – point iii (new) (iii) communication /dissemination capabilities
Amendment 140 #
Proposal for a regulation Article 26 – paragraph 1 – point iv (new) (iv) geographical coverage of several Member States, with preference for a balanced coverage;
Amendment 141 #
Proposal for a regulation Article 26 – paragraph 4 4. On the request of the Coordination Group, the Commission shall invite
Amendment 142 #
Proposal for a regulation Article 27 – paragraph 1 a (new) 1 a. Following the end of the transitional period referred to in Article 33(1), with respect to medicinal products, the identification of emerging health technologies shall follow the EMA pre- notification of medicinal products prior to marketing authorisation applications.
Amendment 143 #
Proposal for a regulation Article 27 – paragraph 2 2. The Commission shall ensure
Amendment 144 #
Proposal for a regulation Article 27 – paragraph 2 – point 1 (new) (1) 3.Common rules on Data a) The Commission shall be empowered to adopt delegated acts in accordance with Article 31 concerning data collection, interoperability of data and the comparability of data. b) The confidential handling of data shall be safeguarded at all times
Amendment 145 #
Proposal for a regulation Article 27 – paragraph 2 a (new) 2 a. All confidential data provided by a manufacturer shall be covered by a clear confidentiality agreement. The Commission shall also ensure the protection of confidential data against unauthorised access or disclosure, and ensure the integrity of data stored against accidental or unauthorised destruction, accidental loss or alteration.
Amendment 146 #
Proposal for a regulation Article 31 Amendment 147 #
Proposal for a regulation Article 32 – paragraph 2 2. When preparing those implementing and delegated acts, the Commission shall take into account the distinctive characteristics of the medicinal product and medical device sectors and shall consider the work already undertaken in the EUnetHTA Joint Actions.
Amendment 148 #
Proposal for a regulation Article 34.º – paragraph 1 1. Member States may carry out a clinical assessment using means other than the rules provided for in Chapter III of this Regulation, on grounds related to the need to protect public health in the Member State concerned
Amendment 149 #
Proposal for a regulation Article 34.º – paragraph 3 Amendment 24 #
Proposal for a regulation Citation 1 Having regard to the Treaty on the Functioning of the European Union, and in particular Article 1
Amendment 25 #
Proposal for a regulation Recital 2 (2) Health Technology Assessment (HTA) is an evidence-based, multidisciplinary process that allows competent authorities to determine the relative effectiveness of new or existing health technologies and should be carried out in a systematic, independent and transparent manner. HTA focuses specifically on the added value of a health technology in comparison with other new or existing health technologies.
Amendment 26 #
Proposal for a regulation Recital 2 (2) Test Health Technology Assessment (HTA) is an evidence-based process that
Amendment 27 #
Proposal for a regulation Recital 3 (3) HTA covers both clinical and non- clinical aspects of a health technology. The EU co-funded joint actions on HTA (EUnetHTA Joint Actions) have identified nine domains by reference to which health technologies are assessed. Of these nine domains, four are clinical and five are non- clinical. The four clinical domains of assessment concern the identification of a health problem and current technology, the examination of the technical characteristics of the technology under assessment, its relative safety, and its relative clinical effectiveness. The five non-clinical assessment domains concern cost and economic evaluation of a technology, its ethical, organisational, social, and legal aspects. The clinical domains are therefore more suited to joint assessment at EU-level on their scientific evidence base
Amendment 28 #
Proposal for a regulation Recital 4 (4) The outcome of HTA is used to inform decisions concerning the allocation of budgetary resources in the field of health, for example, in relation to establishing the pricing or reimbursement levels of health technologies. HTA can therefore assist Member States in creating and maintaining sustainable and comprehensive healthcare systems
Amendment 29 #
Proposal for a regulation Recital 8 (8) The European Parliament, in its resolution of 2 March 2017 on EU options for improving access to medicines,9 called on the Commission to propose legislation on a European system for health technology assessment as soon as possible and to harmonise transparent health technology assessment criteria in order to assess the added therapeutic value of
Amendment 30 #
Proposal for a regulation Recital 11 (11) In accordance with Article 168(7) of the Treaty on the Functioning of the European Union (TFEU), the Member States remain responsible for the organisation and delivery of their healthcare. As such, it is appropriate to limit the scope of Union rules to those aspects of HTA that relate to the clinical assessment of a health technology
Amendment 31 #
Proposal for a regulation Recital 11 (11) In accordance with Article 168(7) of the Treaty on the Functioning of the European Union (TFEU), the Member States remain responsible for the organisation and delivery of their healthcare. As such, it is appropriate to limit the scope of Union rules to those aspects of HTA that relate to the clinical assessment of a health technology
Amendment 32 #
Proposal for a regulation Recital 12 (12) In order to ensure a wide application of harmonised rules on clinical aspects of HTA and enable pooling of expertise and resources across HTA bodies, it is appropriate to require joint clinical assessments to be carried out for all medicinal products undergoing the central marketing authorisation procedure provided for under Regulation (EC) No 726/2004 of the European Parliament and of the Council,11 which incorporate a new active substance, and where those medicinal products are subsequently authorised for a new therapeutic indication. Joint clinical assessments should also be carried out on certain medical devices within the meaning of Regulation (EU) 2017/745 of the European Parliament and of the Council
Amendment 33 #
Proposal for a regulation Recital 14 (14) A coordination group composed of representatives from Member States' health technology assessment of national and regional authorities and bodies should be established with responsibility for overseeing the carrying out of joint clinical assessments and other joint work.
Amendment 34 #
Proposal for a regulation Recital 15 (15) In order to ensure a Member-State led approach to joint clinical assessments and scientific consultations, Member States should designate national HTA authorities and bodies which inform decision-making as members of the Coordination Group. The designated authorities and research bodies should ensure an appropriately high level of representation in the Coordination Group and technical expertise in its sub- groups, taking into account the need to provide expertise on the HTA of medicinal products and medical devices.
Amendment 35 #
Proposal for a regulation Recital 16 (16) In order that the harmonised procedures fulfil their internal market objective, Member States should be required to take full account of the results of joint clinical assessments and not repeat those assessments. Compliance with this obligation does not prevent Member States from carrying out additional clinical analyses to the extent that they are missing from the joint clinical assessment and are deemed necessary within the national health technology assessment context. Member States remain free to carry out non-clinical assessments on the same health technology, or from drawing conclusions on the added value of the technologies concerned as part of national appraisal processes which may consider clinical as well as non-clinical data and criteria. It also does not prevent Member States from forming their own recommendations or decisions on pricing or reimbursement.
Amendment 36 #
Proposal for a regulation Recital 16 (16) In order that the harmonised procedures fulfil their internal market objective, Member States should be required to take full account of the results of joint clinical assessments and not repeat those assessments.
Amendment 37 #
Proposal for a regulation Recital 16 (16) In order t
Amendment 38 #
Proposal for a regulation Recital 19 a (new) (19 a) The health technology assessment work covered under this Regulation should be separate and distinct from regulatory assessments of the safety and performance of health technologies carried out pursuant to other Union legislation and have no bearing on other aspects unrelated to the subject matter of this Regulation adopted in accordance with other Union legislation.
Amendment 39 #
Proposal for a regulation Recital 19 a (new) (19 a) The health technology assessment work covered under this Regulation should be separate and distinct from regulatory assessments of the safety and efficacy of health technologies carried out pursuant to other Union legislation and have no bearing on other aspects unrelated to the subject matter of this Regulation adopted in accordance with other Union legislation.
Amendment 40 #
Proposal for a regulation Recital 21 Amendment 41 #
Proposal for a regulation Recital 21 a (new) (21 a) Joint scientific consultations shall concern the clinical study design, the determination of best comparators based on the best medical practice in the interest of patients. The process should be transparent. Joint scientific consultations results shall be made available to the general public.
Amendment 42 #
Proposal for a regulation Recital 24 (24) In order to ensure the inclusiveness and transparency of the joint work, the Coordination Group should engage and consult widely with interested parties and stakeholders. However, in order to preserve the integrity of the joint work, rules should be developed to ensure the independence and impartiality of the joint work and ensure that such consultation does not give rise to any conflicts of interest. Furthermore, these rules and all consultations must be made public.
Amendment 43 #
Proposal for a regulation Recital 25 (25) In order to ensure a uniform approach to the joint work provided for in this Regulation, implementing powers should be conferred on the Commission to establish a common procedural and methodological framework for clinical assessments, procedures for joint clinical assessments and procedures for joint scientific consultations. Where appropriate, distinct rules should be developed for medicinal products and medical devices. In the development of such rules, the Commission should take into account the results of the work already undertaken in the EUnetHTA Joint Actions and in particular the methodological guidelines and evidence submission template. It should also take into account initiatives on HTA funded through the Horizon 2020 research programme, as well as regional initiatives on HTA
Amendment 44 #
Proposal for a regulation Recital 25 (25) In order to ensure a uniform approach to the joint work provided for in this Regulation,
Amendment 45 #
Proposal for a regulation Recital 25 (25) In order to ensure a uniform approach to the joint work provided for in this Regulation,
Amendment 46 #
Proposal for a regulation Recital 25 (25) In order to ensure a uniform approach to the joint work provided for in this Regulation,
Amendment 47 #
Proposal for a regulation Recital 25 (25) In order to ensure a uniform approach to the joint work provided for in this Regulation,
Amendment 48 #
Proposal for a regulation Recital 26 (26) In order to ensure that this Regulation is fully operational and to adapt it to technical and scientific development, the
Amendment 49 #
Proposal for a regulation Recital 26 (26) In order to ensure that this Regulation is fully operational and to adapt it to technical and scientific development, the power to adopt acts in accordance with Article 290 of the Treaty on the Functioning of the European Union should be delegated to the Commission in respect of the contents of documents to be submitted, reports, and summary reports of clinical assessments, the contents of documents for requests, and reports of joint scientific consultations, and the rules for selecting stakeholders, but with the obligation to periodically inform the European Parliament and the Council of these documents and reports. It is of particular importance that the Commission carries out appropriate consultations during its preparatory work, including at expert level, and that those consultations be conducted in accordance with the principles laid down in the Interinstitutional Agreement on Better Law-Making of 13 April 2016.14 In particular, to ensure equal participation in the preparation of delegated acts, the European Parliament and the Council should receive all documents at the same time as Member States' experts, and their experts systematically should be granted access to meetings of Commission expert groups dealing with the preparation of delegated acts.
Amendment 50 #
Proposal for a regulation Recital 27 (27) In order to ensure that sufficient resources are available for the joint work and stable administrative support provided for under this Regulation, the Union should
Amendment 51 #
Proposal for a regulation Recital 28 (28) In order to facilitate the joint work and the exchange of information between Member States on HTA, provision should be made for the establishment of an IT platform that contains appropriate databases and secure channels for communication. The Commission should also ensure a link between the IT platform and other data infrastructures relevant for the purposes of HTA such as registries of real world data. The IT platform should ensure the publication and transparency for both the joint scientific consultations and the joint technology assessment, regarding all the clinical data employed, the studies, the methodology, the clinical results, the stakeholders consulted, the observations made, and the final reports.
Amendment 52 #
Proposal for a regulation Recital 31 (31) In order to ensure that the support framework continues to be as efficient and cost-effective as possible, the Commission should report on the implementation of the provisions on the scope of the joint clinical assessments and on the functioning of the support framework no later than two years after the end of the transitional period.
Amendment 53 #
Proposal for a regulation Recital 32 (32) The Commission should carry out an evaluation of this Regulation. Pursuant to paragraph 22 of the Interinstitutional Agreement on Better Law-Making of 13 April 2016, that evaluation should be based on the five criteria of efficiency, effectiveness, relevance, coherence and EU added value and should be supported by a monitoring programme. The results must also be communicated to the European Parliament and Council for approval.
Amendment 54 #
Proposal for a regulation Article 1 – paragraph 1 – introductory part 1. Taking into account the results of the work already undertaken in the EUnetHTA Joint Actions, this Regulation establishes:
Amendment 55 #
Proposal for a regulation Article 1.º – paragraph 2 a (new) 2a. This regulation must aim to foster and strengthen national health systems by promoting measures for research into and the production and distribution of health technologies, with free, universal access.
Amendment 56 #
Proposal for a regulation Article 2 – paragraph 1 – point e (e) 'clinical assessment' means a compilation and evaluation of the available scientific evidence on a health technology in comparison with one or more other health technologies based on the following clinical domains of health technology assessment: the description of the health problem addressed by the health technology and the current use of other health technologies addressing that health problem, the description and technical characterisation of the health technology, the relative clinical effectiveness, and the relative safety of the health technology, which, for medicinal products shall occur at the time of regulatory approval, whereas for medical devices may occur following market launch of medical devices;
Amendment 57 #
Proposal for a regulation Article 2 – paragraph 1 – point g a (new) (g a) ‘patient-relevant health outcomes’ means data that captures or predicts mortality, morbidity, health-related quality of life, including pain, recovery rates, length of stay in hospitals and adverse events, including re-admissions, complications, blood loss, infections;
Amendment 58 #
Proposal for a regulation Article 3 – paragraph 2 2. Member States shall designate their national authorities and bodies responsible for health technology assessment which inform decision-making as members of the Coordination Group and its sub-groups and inform the Commission thereof and of any subsequent changes. Member States
Amendment 59 #
Proposal for a regulation Article 3 – paragraph 3 3. The Coordination Group shall act by consensus, or, where n
Amendment 60 #
Proposal for a regulation Article 3.º – paragraph 3 3. The Coordination Group shall act by consensus
Amendment 61 #
Proposal for a regulation Article 3 – paragraph 4 4. Meetings of the Coordination Group shall be co-chaired by the Commission without the right to vote and a co-chair elected from the members of the group for a set term to be determined in its rules of procedure.
Amendment 62 #
Proposal for a regulation Article 3 – paragraph 6 6. Members of the Coordination Group, and their appointed representatives shall respect the principles of transparency, independence, impartiality, and confidentiality for specific information.
Amendment 63 #
Proposal for a regulation Article 3 – paragraph 7 7. The Commission shall publish a list of the designated members of the Coordination Group and its sub-groups on the IT platform referred to in Article 27. The Commission shall regularly update any changes to this list or related information to the Coordination Group.
Amendment 64 #
Proposal for a regulation Article 3 – paragraph 8 – point a a (new) (a a) adopts rules on conflict of interest for the functioning of the coordination groups and the conduction of joint clinical assessments and joint scientific consultations.
Amendment 65 #
Proposal for a regulation Article 3 – paragraph 8 – point a a (new) (a a) conduct health technology assessments activities and manage the general governance of joint works in an independent and transparent way;
Amendment 66 #
Proposal for a regulation Article 3 – paragraph 8 – point c (c) ensure cooperation with all relevant Union level bodies to facilitate additional evidence generation necessary for its work;
Amendment 67 #
Proposal for a regulation Article 3 – paragraph 8 – point d (d) ensure appropriate involvement of all relevant stakeholders in its work;
Amendment 68 #
Proposal for a regulation Article 3 – paragraph 8 – point d (d) ensure appropriate and regular involvement of stakeholders in its work;
Amendment 69 #
Proposal for a regulation Article 3 – paragraph 8 – point e – point iii (iii) identification of emerging health technologies, following the end of the transitional period referred to in Article33(1), with respect to medicinal products, the identification of emerging health technologies shall follow the EMA pre-notification of medicinal products prior to marketing authorisation applications;
Amendment 70 #
Proposal for a regulation Article 3 – paragraph 10 a (new) 10 a. Each national authority and body responsible for health technology assessment as members of the Coordination Group and its sub-groups, and each member and staff of each national authority and body responsible for health technology assessment shall in accordance with Union or Member State law be subject to a duty of professional secrecy both during and after their term of office, with regard to any confidential information which has come to their knowledge in the course of the performance of their tasks or exercise of their powers.
Amendment 71 #
Proposal for a regulation Article 4 – paragraph 3 – point c (c) consult the Commission on the draft annual work programme
Amendment 72 #
Proposal for a regulation Article 4 – paragraph 3 – point c a (new) (c a) take into account that following the end of the transitional period referred to in Article33(1), with respect to medicinal products, the identification of emerging health technologies shall follow the EMA pre-notification of medicinal products prior to marketing authorisation applications
Amendment 73 #
Proposal for a regulation Article 5 – paragraph 1 – point a (a) medicinal products subject to and at the time of the authorisation procedure provided for in Regulation (EC) No 726/2004, including where an amendment has been made to the Commission Decision to grant a marketing authorisation based on a change in the therapeutic indication or indications for which the original authorisation was granted, with the exception of medicinal products authorised under Articles 10 and 10a of Directive 2001/83/EC, and those medicinal products authorised under Article 8 (3) of Directive 2001/83/EC not incorporating a new active substance;
Amendment 74 #
Proposal for a regulation Article 5 – paragraph 1 – point b a (new) (b a) other medical devices considered to be major innovation or with potential significant impact on national health care systems.
Amendment 75 #
Proposal for a regulation Article 5 – paragraph 1 – point c a (new) (c a) other medical devices considered to be of interest on the basis of the criteria set out in paragraph 2.
Amendment 76 #
Proposal for a regulation Article 5 – paragraph 2 – introductory part 2. The Coordination Group shall select the medical devices referred to in paragraph 1 points (b), (ba) and (c) for joint clinical assessment based on the following criteria:
Amendment 77 #
Proposal for a regulation Article 5 a (new) Article 5 a Methodological standards 1. Joint clinical assessments should be based on standards of evidence-based medicine. The added therapeutic value should be demonstrated on patient- relevant endpoints: mortality, morbidity, quality of life, according to the situation. 2.The manufacturers shall provide all data from all sponsored studies in the indication under assessment. In case of non-compliance to provide full data, the joint assessment will be interrupted or even discontinued. The names of those manufactories who failed to provide all the necessary data, shall be made public.
Amendment 78 #
Proposal for a regulation Article 5 b (new) Article 5 b Conduct of Comparative trials against standart treatment 1. Health technology developers shall conduct at least one randomized clinical trial comparing their new drug with an active comparator considered among the best current proven intervention at the time the trial was designed (standard treatment), or the most common intervention when no standard treatment exists. The developer is expected to comply with established guidelines on development of products and to take into account the current medical knowledge to establish the best comparative alternative. 2. Full results of comparative trials, including raw and individual patient data (clinical study reports) should be made available at the time of applications for a marketing authorization and included in HTA applications. As soon as the joint clinical assessment is finalized, all information and datas should be made publicly available as provided for by Regulation 1049/2001. 3.If the developer obtained scientific advice on data and evidence requirements, and did not follow the advice, the developer will be asked to justify the deviation from the advice given.
Amendment 79 #
Proposal for a regulation Article 6 – paragraph 1 – subparagraph 1 The Coordination Group shall initiate joint clinical assessments of health technologies on the basis of its annual work programme by designating a sub-group to oversee the preparation of the joint clinical assessment report on behalf of the Coordination Group. With respect to medicinal products, the Coordination Group shall initiate joint clinical assessments in accordance with the EMA pre-notification of medicinal products prior to marketing authorisation applications.
Amendment 80 #
Proposal for a regulation Article 6 – paragraph 2 2. The designated sub-group shall
Amendment 81 #
Proposal for a regulation Article 6 – paragraph 2 2. The designated sub-group shall
Amendment 82 #
Proposal for a regulation Article 6 – paragraph 2 2. The designated sub-group shall request relevant health technology developers to submit comprehensive documentation containing the information, all available data and evidence, including both negative and positive results as well as studies in which the technology has been use, necessary for the joint clinical assessment.
Amendment 83 #
Proposal for a regulation Article 6 – paragraph 5 – point a (a) a
Amendment 84 #
Proposal for a regulation Article 6 – paragraph 8 Amendment 85 #
Proposal for a regulation Article 6 – paragraph 9 9. The designated sub-group shall ensure that stakeholders experts, including patients and clinical experts identified to by the Stakeholder network or by the health technology developer, are given an opportunity to provide comments during the preparation of the draft joint clinical assessment report and the summary report and set a time-frame in which they may submit comments.
Amendment 86 #
Proposal for a regulation Article 6 – paragraph 10 10. Following receipt and consideration of any comments provided in accordance with paragraphs 7,
Amendment 87 #
Proposal for a regulation Article 6 – paragraph 12 12. The Coordination Group shall approve the final joint clinical assessment report and summary report, wherever possible by consensus or, where necessary, by a
Amendment 88 #
Proposal for a regulation Article 6 – paragraph 13 Amendment 89 #
Proposal for a regulation Article 6 – paragraph 13 13. The assessor shall ensure the removal of any information of a commercially sensitive nature from the approved joint clinical assessment report and the summary report. The assessor shall consult the developer on the report before its publication. The developer shall have a period of 7 working days to point out which information it considers confidential and to justify the commercially sensitive nature of that information.
Amendment 90 #
Proposal for a regulation Article 7 – paragraph 1 1. Where the Commission considers that the approved joint clinical assessment report and summary report comply with the
Amendment 91 #
Proposal for a regulation Article 7 – paragraph 2 2. Where, within 30 days of receipt of the approved joint clinical assessment report and the summary report, the Commission concludes that the approved joint clinical assessment report and summary report do not comply with the
Amendment 92 #
Proposal for a regulation Article 7 – paragraph 4 4. Following the submission of the modified approved joint clinical assessment report and summary report, and where the Commission considers that the modified approved joint clinical assessment report and summary report comply with the
Amendment 93 #
Proposal for a regulation Article 7 – paragraph 5 5. If the Commission concludes that the modified approved joint clinical assessment report and summary report do not comply with the
Amendment 94 #
Proposal for a regulation Article 8 – paragraph 1 – point a (a) not carry out a clinical assessment or an equivalent assessment process on a health technology included in the List of Assessed Health Technologies or for which a joint clinical assessment has been initiated; Member States shall have the right to complement the clinical evidence in the joint clinical assessment report according to their national context. Additional clinical evidence cannot deny the conclusions reached in the joint clinical assessment report.
Amendment 95 #
Proposal for a regulation Article 8 – paragraph 1 – point a (a) not carry out a clinical assessment or an equivalent assessment process on a health technology included in the List of Assessed Health Technologies or for which a joint clinical assessment has been initiated; According to the national needs, Member States shall have the right to complement the report with additional clinical evidence.
Amendment 96 #
Proposal for a regulation Article 8 – paragraph 1 – point a a (new) (a a) Paragraph 1(b) shall not prevent Member States from carrying out assessments on the added clinical value of the technologies concerned as part of national or regional appraisal processes which may consider clinical as well as non- clinical data and evidence specific to the Member Sates concerned which did not form part of the joint clinical assessment and witch are necessary to complete the general assessment of healthy technology.
Amendment 97 #
Proposal for a regulation Article 8 – paragraph 2 2. Member States shall notify the Commission of the outcome of a health technology assessment on a health technology which has been subject to a joint clinical assessment within 30 days from its completion. That notification shall be accompanied by information on how the conclusions of the joint clinical assessment report have been applied in the overall health technology assessment. the final report must be made publicly available. The Commission shall facilitate the exchange of this information between Member States through the IT platform referred to in Article 27.
Amendment 98 #
Proposal for a regulation Article 9 – paragraph 1 – point b a (new) (b a) the health technology developer requests an update on the grounds that additional evidence is made available for which the Coordination Group would need to reconsider the conclusions of the initial assessment.
Amendment 99 #
Proposal for a regulation Article 9 a (new) Article 9 a 1. The Coordination Group should consider to carry out updates of joint clinical assessments at the moment of the renewal of the marketing authorization after five years pursuant to Article 14 of Regulation (EU)726/2004. 2. Should additional important evidence becomes available significantly prior to the renewal of the marketing authorisation, the Coordination Group should also consider carrying out an update on joint clinical assessment.
source: 622.255
2018/06/13
IMCO
144 amendments...
Amendment 100 #
Proposal for a regulation Article 6 – paragraph 8 Amendment 101 #
Proposal for a regulation Article 6 – paragraph 9 9. The designated sub-group shall ensure that stakeholders, including patients and clinical experts, civil society organisations, patient associations, social partners, consumer organisations, healthcare professionals and non- governmental organisations, are given an opportunity to provide comments during the preparation of the draft joint clinical assessment report and the summary report and set a time-frame in which they may submit comments.
Amendment 102 #
Proposal for a regulation Article 6 – paragraph 10 10. Following receipt and consideration of any comments provided in accordance with paragraphs 7,
Amendment 103 #
Proposal for a regulation Article 6 – paragraph 12 12. The Coordination Group shall approve the final joint clinical assessment report and summary report, wherever possible by consensus or, where necessary, by a
Amendment 104 #
Proposal for a regulation Article 6 – paragraph 12 12. The Coordination Group shall approve the final joint clinical assessment report and summary report, wherever possible by consensus or, where necessary, by a
Amendment 105 #
Proposal for a regulation Article 6 – paragraph 13 Amendment 106 #
Proposal for a regulation Article 6 – paragraph 13 13. The assessor shall ensure the removal of any information of a commercially sensitive nature from the approved joint clinical assessment report and the summary report. The assessor shall consult the developer on the report before its publication. The developer shall have a period of 30 working days to respond in order to identify any information it considers confidential and to justify the commercially sensitive nature of that information. In the event of disagreement between the assessor and the developer, the assessor and the co- assessor shall decide.
Amendment 107 #
Proposal for a regulation Article 6 – paragraph 14 a (new) 14 a. When receiving the joint clinical assessment report and the summary report, the health technology developer may hand in a detailed objection in writing to the Coordination Group within seven working days. The Coordination Group shall evaluate the objections within 30 working days and may revise the report if necessary. It shall approve and submit the final joint clinical assessment report, the summary report and an explanatory document setting out how the objections were addressed.
Amendment 108 #
Proposal for a regulation Article 7 – paragraph 1 1. Where the Commission considers that the approved joint clinical assessment report and summary report comply with the
Amendment 109 #
Proposal for a regulation Article 7 – paragraph 2 2. Where, within 30 days of receipt of the approved joint clinical assessment report and the summary report, the Commission concludes that the approved joint clinical assessment report and summary report do not comply with the
Amendment 110 #
Proposal for a regulation Article 7 – paragraph 4 4. Following the submission of the modified approved joint clinical assessment report and summary report, and where the Commission considers that the modified approved joint clinical assessment report and summary report comply with the
Amendment 111 #
Proposal for a regulation Article 7 – paragraph 5 5. If the Commission concludes that the modified approved joint clinical assessment report and summary report do not comply with the
Amendment 112 #
Proposal for a regulation Article 8 – paragraph 1 – introductory part 1. Member States
Amendment 113 #
Proposal for a regulation Article 8 – paragraph 1 – point a Amendment 114 #
Proposal for a regulation Article 8 – paragraph 1 – point a (a) not carry out a clinical assessment or an equivalent assessment process on a health technology included in the List of Assessed Health Technologies or for which a joint clinical assessment has been initiated. According to the national needs, Member States shall have the right to complement the report with additional clinical evidence;
Amendment 115 #
Proposal for a regulation Article 8 – paragraph 1 – point a (a)
Amendment 116 #
Proposal for a regulation Article 8 – paragraph 1 – point a (a) not carry out
Amendment 117 #
Proposal for a regulation Article 8 – paragraph 1 – point b (b)
Amendment 118 #
Proposal for a regulation Article 8 – paragraph 1 – point b (b)
Amendment 119 #
Proposal for a regulation Article 8 – paragraph 1 – point b – point i (new) i) Paragraph 1(b) shall not prevent Member States from carrying out assessments on the added clinical value of the technologies concerned as part of national or regional appraisal processes which may consider clinical as well as non-clinical data and evidence specific to the Member State concerned which did not form part of the joint clinical assessment and which are necessary to complete the general assessment of health technology.
Amendment 120 #
Proposal for a regulation Article 8 – paragraph 1 a (new) 1 a. The requirement set out in point (a) of paragraph 1 shall not prevent Member States from carrying out additional assessments on the added clinical value of the health technology concerned, as part of national or regional appraisal processes, which may consider clinical evidence specific to the Member State concerned, as long as they are not included in the joint clinical assessment and are necessary to complete the pricing and reimbursement process.
Amendment 121 #
Proposal for a regulation Article 8 – paragraph 2 2. Member States shall notify the Commission of the outcome of a health technology assessment on a health technology which has been subject to a joint clinical assessment within 30 days from its completion. That notification shall be accompanied by information on how the conclusions of the joint clinical assessment report have been applied in the overall health technology assessment. The final report must be made publicly available. The Commission shall facilitate the exchange of this information between Member States through the IT platform referred to in Article 27.
Amendment 122 #
Proposal for a regulation Article 8 – paragraph 2 2. Member States
Amendment 123 #
Proposal for a regulation Article 9 a (new) Article 9 a 1. The Coordination Group may consider to carry out updates of joint clinical assessments at the moment of the renewal of the marketing authorization after five years pursuant to Article 14 of Regulation (EU)726/2004. 2. Should additional important evidence become available significantly prior to the renewal of the marketing authorisation, the Coordination Group may also consider carrying out an update on joint clinical assessment.
Amendment 124 #
Proposal for a regulation Article 10 – paragraph 1 – point a – point ii (ii) select medicinal products referred to in Article 5(1)(a) for joint clinical assessment based on the following selection criteria
Amendment 125 #
Proposal for a regulation Article 10 – paragraph 1 – point a – point ii – point a (new) a) unmet medical needs, where there is no treatment or only unsatisfactory treatment available;
Amendment 126 #
Proposal for a regulation Article 10 – paragraph 1 – point a – point ii – point b (new) b) potential impact on patients and public health, considering, inter alia, the burden of disease measured by mortality and morbidity, and the life-threatening or chronically debilitating nature of the disease targeted by the health technology;
Amendment 127 #
Proposal for a regulation Article 10 – paragraph 1 – point a – point ii – point c (new) c) significant cross-border dimension;
Amendment 128 #
Proposal for a regulation Article 10 – paragraph 1 – point a – point ii – point d (new) d) the available resources of the Coordination Group.
Amendment 129 #
Proposal for a regulation Article 11 – paragraph 1 – introductory part 1. The Co
Amendment 130 #
Proposal for a regulation Article 11 – paragraph 1 – point a (a) submissions of information, data and evidence by health technology developers, including the protection of developers' confidential information;
Amendment 131 #
Proposal for a regulation Article 11 – paragraph 1 – point f Amendment 132 #
Proposal for a regulation Article 11 – paragraph 1 – point f (f) cooperation
Amendment 133 #
Proposal for a regulation Article 11 – paragraph 2 Amendment 134 #
Proposal for a regulation Article 13 – paragraph 2 2. The designated sub-group shall request the health technology developer to submit the documentation containing the information, data and evidence necessary for the joint scientific consultation. All relevant data and information shall be available to the public.
Amendment 135 #
Proposal for a regulation Article 13 – paragraph 3 3. The designated sub-group shall appoint from among its members, an assessor and a co-assessor, from different Member States, with responsibility for conducting the joint scientific consultation. The appointments shall take into account the scientific expertise necessary for the assessment.
Amendment 136 #
Proposal for a regulation Article 13 – paragraph 8 8. The designated sub-group shall ensure that stakeholders, including patients, consumers and clinical experts are given an opportunity to provide comments during the preparation of the draft joint scientific consultation report and set a time-frame in which they may submit comments.
Amendment 137 #
Proposal for a regulation Article 13 – paragraph 12 12. The Coordination Group shall approve the final joint scientific consultation report, wherever possible by consensus or, where necessary, by a
Amendment 138 #
Proposal for a regulation Article 13 – paragraph 12 12. The Coordination Group shall approve the final joint scientific consultation report, wherever possible by consensus or, where necessary, by a simple majority of Member States, at the latest
Amendment 139 #
Proposal for a regulation Article 13 – paragraph 12 12. The Coordination Group shall approve the final joint scientific consultation report, wherever possible by consensus or, where necessary, by a
Amendment 140 #
Proposal for a regulation Article 13 – paragraph 12 a (new) 12 a. Delegates participating in the elaboration of joint scientific consultations for a health technology shall not participate in the joint clinical assessment of this particular technology.
Amendment 141 #
Proposal for a regulation Article 14 – paragraph 2 2. The Coordination Group shall include anonymised summary information on the joint scientific consultations in its annual reports and the IT platform referred to in Article 27. The scientific consultation reports shall be made public once the joint clinical assessments have been completed.
Amendment 142 #
Proposal for a regulation Article 14 – paragraph 2 2. The Coordination Group shall include
Amendment 143 #
Proposal for a regulation Article 16 – paragraph 1 – point d (d) the consultation of patients, healthcare professionals, clinical experts and other relevant stakeholders;
Amendment 144 #
Proposal for a regulation Article 16 – paragraph 1 – point d (d) the consultation of patients, consumers, clinical experts and other relevant stakeholders;
Amendment 145 #
Proposal for a regulation Article 16 – paragraph 1 – point f Amendment 146 #
Proposal for a regulation Article 17 – paragraph 1 – point b (b) the rules for determining the stakeholders to be consulted for the purpose of this Section. Declarations on conflicts of interest shall be made publicly available for all stakeholder. Experts with conflicts of interest shall not participate in the process.
Amendment 147 #
Proposal for a regulation Article 18 – paragraph 2 – introductory part 2. In the preparation of the study, the Coordination Group shall
Amendment 148 #
Proposal for a regulation Article 18 – paragraph 2 – point b (b) patient and consumer organisations;
Amendment 149 #
Proposal for a regulation Article 18 – paragraph 2 – point c a (new) (c a) healthcare professionals;
Amendment 150 #
Proposal for a regulation Article 18 – paragraph 2 – point e – point i (new) i) civil society organisations, social partners, consumer organisations, healthcare professionals and non- governmental organisations in the field of health technology assessment
Amendment 151 #
Proposal for a regulation Article 19 – paragraph 1 – point b Amendment 152 #
Proposal for a regulation Article 19 – paragraph 1 – point c (c) health technology assessments on health technologies other than medicinal products
Amendment 153 #
Proposal for a regulation Article 19 – paragraph 3 3. The cooperation referred to in paragraph 1 points (b) and (c) may be carried out using the procedural rules established
Amendment 154 #
Proposal for a regulation Article 22 – paragraph 1 – introductory part 1. The Commission shall be empowered to adopt implementing acts in accordance with Article 31 concerning:
Amendment 155 #
Proposal for a regulation Article 22 – paragraph 1 – introductory part 1. The Co
Amendment 156 #
Proposal for a regulation Article 22 – paragraph 1 – introductory part 1. The Co
Amendment 157 #
Proposal for a regulation Article 22 – paragraph 1 – point a – point iii (iii) the consultation of patients, clinical
Amendment 158 #
Proposal for a regulation Article 22 – paragraph 1 – point a – point iii (iii) the consultation of patients, consumers, clinical experts, and other stakeholders in clinical assessments. The declarations of conflicts of interest of consulted stakeholders shall be made publicly available.
Amendment 159 #
Proposal for a regulation Article 22 – paragraph 1 – point a – point iii (iii) the consultation of patients, healthcare professionals, clinical experts, and other stakeholders in clinical assessments.
Amendment 160 #
Proposal for a regulation Article 22 – paragraph 1 – point b Amendment 161 #
Proposal for a regulation Article 22 – paragraph 1 a (new) 1 a. The methodologies referred to in point (b) of paragraph 1 shall be developed on the basis of the existing EUnetHTA methodological guidelines and evidence submission templates. They shall be developed and agreed after consultations with all stakeholders, regularly updated to reflect the scientific evolution and shall be made publicly available.
Amendment 162 #
Proposal for a regulation Article 22 – paragraph 2 Amendment 163 #
Proposal for a regulation Article 22 – paragraph 2 a (new) 2 a. The Coordination Group shall draw up the methodologies to be used to carry out joint clinical assessments and consultations and shall define the content of those assessments and consultations. In any event: (a) the methodologies shall be based on high standards of quality, the best available scientific evidence, stemming primarily from double-blind randomised clinical trials, meta-analysis and systematic reviews; (b) the assessment of relative effectiveness shall be based on end-points which are relevant to the patient with useful, relevant, tangible and specific criteria suited to the clinical situation concerned; c) the comparators shall be the reference comparators for the clinical entity concerned and be the best and/or most commonly used technological or process based comparator; d) the technology developers shall, for the purpose of its clinical assessment, provide the Coordination Group with the complete dossier in eCTD format submitted to the European Medicines Agency for centralised authorisation. This package shall include the Clinical Study Report and the data of individual patients in all clinical trials; e) the information to be provided by the health technology developer shall relate to the most up-to-date and public research. Failure to comply with this requirement may trigger a sanctions mechanism. Any flexibility in the methodology shall be exceptional and adapted to very specific circumstances, but never to the detriment of the quality of health technologies or clinical evidence. The methodology must guarantee high quality and high clinical evidence. Since clinical trials are the studies par excellence in the biomedical field, the use of another type of study shall be exceptional and fully justified. The rules to be developed by the Coordination Group shall cover the possibilities for improvement of clinical evidence in the cases where further scientific evidence is needed.
Amendment 164 #
Proposal for a regulation Article 23 – paragraph 1 – introductory part The Co
Amendment 165 #
Proposal for a regulation Article 24 – paragraph 2 2. The funding referred to in paragraph 1 shall include funding for the participation of Member States' designated health technology authorities and bodies in support of the work on joint clinical assessments and joint scientific consultations. Assessor and co-assessors shall be entitled to a special allowance, approved by the Commission, compensating them for their work on joint clinical assessments and joint scientific consultations in accordance with internal Commission provisions.
Amendment 166 #
Proposal for a regulation Article 24 – paragraph 2 – point 1 (new) (1) The Union shall guarantee a sufficient, stable and continuing public funding of the Coordination Group. In any case, this public funding shall be conducted without any direct or indirect involvement of HTA developers.
Amendment 167 #
Proposal for a regulation Article 25 – paragraph 1 – point f Amendment 168 #
Proposal for a regulation Article 26 – paragraph 1 1. The Commission shall establish a stakeholder network through an open call for applications and a selection of suitable stakeholder organisations based on selection criteria established in the open call for applications. The stakeholder organisation shall at least have members of civil society organisations, patient associations, social partners, consumer organisations, healthcare professionals and non-governmental organisations dealing with health technology assessment.
Amendment 169 #
Proposal for a regulation Article 26 – paragraph 1 – point 1 (new) (1) The European Parliament shall also have a qualified representative in the stakeholder network. The representative shall report to the European Parliament on a regular basis about the recent developments within the stakeholder network.
Amendment 170 #
Proposal for a regulation Article 26 – paragraph 2 2. The Commission shall publish the list of stakeholder organisations included in the stakeholder network. In any case, all members of the stakeholder network shall have no conflict of interest with and shall not be receiving any funding from health technology developers.
Amendment 171 #
Proposal for a regulation Article 26 – paragraph 3 – introductory part 3. The Commission shall organise
Amendment 172 #
Proposal for a regulation Article 26 – paragraph 3 – point a (a) update stakeholders on the work of the group; all members of the stakeholder network shall have access to all relevant data and information;
Amendment 173 #
Proposal for a regulation Article 26 – paragraph 3 – point b (b) provide for an exchange of information
Amendment 174 #
Proposal for a regulation Article 26 – paragraph 4 4. On the request of the Coordination Group, the Commission shall invite patients, healthcare professionals and clinical experts nominated by the stakeholder network to attend meetings of the Coordination Group as observers.
Amendment 175 #
Proposal for a regulation Article 27 – paragraph 2 a (new) 2 a. All confidential data provided by a manufacturer shall be covered by a clear confidentiality agreement. The Commission shall also ensure the protection of confidential data against unauthorised access or disclosure, and ensure the integrity of data stored against accidental or unauthorised destruction, accidental loss or alteration.
Amendment 176 #
Proposal for a regulation Article 27 a (new) Article 27 a Common rules on data 1. The Commission shall be empowered to adopt delegated acts in accordance with Article 31 concerning data collection, interoperability of data and the comparability of data. 2. Assessors and co-assessors shall have full access to the data used by the authorities responsible for granting the marketing authorisation of a medicinal product, as well as the possibility of using or generating additional relevant data for the purposes of assessing a medicinal product in the context of a joint HTA. 3. The confidential handling of data shall be safeguarded at all times.
Amendment 177 #
Proposal for a regulation Article 29 – paragraph 1 1. No later than f
Amendment 178 #
Proposal for a regulation Article 31 Amendment 179 #
Proposal for a regulation Article 32 – paragraph 2 2. When preparing those implementing and delegated acts, the Commission shall take into account the distinctive characteristics of the medicinal product
Amendment 180 #
Proposal for a regulation Article 34 – paragraph 1 1. Member States may carry out a clinical assessment using means other than the rules provided for in Chapter III of this Regulation, namely on grounds related to the need to protect public health in the Member State concerned and provided the measure is justified, necessary and proportionate as regards achieving that aim.
Amendment 181 #
Proposal for a regulation Article 34 – paragraph 3 3. The Commission shall, within
Amendment 38 #
Proposal for a regulation Recital 1 (1) The development of health technologies is a key
Amendment 39 #
Proposal for a regulation Recital 2 (2) Health Technology Assessment (HTA) is an evidence-based process
Amendment 40 #
Proposal for a regulation Recital 4 (4) The outcome of HTA is used to inform decisions concerning the allocation of budgetary resources in the field of health, for example, in relation to establishing the pricing or reimbursement levels of health technologies. HTA can therefore assist Member States in creating and maintaining sustainable healthcare systems and to stimulate innovation that delivers better outcomes for patients, while patients have the right to health protection and protection against the financial, social and medical consequences of the disease, as well as unrestrained access to the latest therapeutic discoveries, which should be guaranteed by law in all Member States.
Amendment 41 #
Proposal for a regulation Recital 4 (4) The outcome of HTA is used to inform decisions concerning the allocation of budgetary resources in the field of health, for example, in relation to establishing the pricing or reimbursement levels of health technologies. HTA can therefore assist Member States in creating and maintaining sustainable healthcare systems and to stimulate innovation that delivers better outcomes for patients and which should aim to achieve the best cost- effectiveness ratio.
Amendment 42 #
Proposal for a regulation Recital 5 a (new) (5 a) A stronger focus should be put on a better and more effective outcome for patients. Therefore, the opinion of civil society organisations, patient associations, social partners, consumer organisations, healthcare professionals and non- governmental organisations dealing with health technology assessment should be taken into consideration for the purposes of clinical assessment of health technologies as provided for in this Regulation.
Amendment 43 #
Proposal for a regulation Recital 12 (12) In order to ensure a wide application of harmonised rules on clinical aspects of HTA and enable pooling of expertise and resources across HTA bodies, it is appropriate to require joint clinical assessments to be carried out for all medicinal products undergoing the central marketing authorisation procedure provided for under Regulation (EC) No 726/2004
Amendment 44 #
Proposal for a regulation Recital 12 (12) In order to ensure a wide application of harmonised rules on clinical aspects of HTA and enable pooling of expertise and resources across HTA bodies, it is appropriate to require joint clinical assessments to be carried out for all medicinal products undergoing the central marketing authorisation procedure provided for under Regulation (EC) No 726/2004 of the European Parliament and of the Council,11 which incorporate a new active substance, and where those medicinal products are subsequently authorised for a new therapeutic indication. Joint clinical assessments should also be carried out on certain medical devices
Amendment 45 #
Proposal for a regulation Recital 13 (13)
Amendment 46 #
Proposal for a regulation Recital 15 (15) In order to ensure a Member-State led approach to joint clinical assessments and scientific consultations, Member States should designate national HTA authorities and bodies which inform decision-making as members of the Coordination Group. The designated authorities and bodies should ensure an appropriately high level of representation in the Coordination Group and technical expertise in its sub- groups, taking into account the need to provide expertise on the HTA of medicinal products
Amendment 47 #
Proposal for a regulation Recital 16 (16) In order that the harmonised procedures fulfil their internal market objective, Member States should be required to take full account of the results of joint clinical assessments and not repeat those assessments.
Amendment 48 #
Proposal for a regulation Recital 16 (16) In order that the harmonised procedures fulfil their internal market objective and at the same time support access to medical innovations, Member States should be required to take full account of the results of joint clinical assessments and not repeat those assessments. Compliance with this obligation does not prevent Member States from carrying out non-clinical assessments on the same health technology, or from drawing conclusions on the clinical added value of the technologies concerned as part of national appraisal processes which may consider clinical as well as non-clinical data and criteria. It also does not prevent Member States from forming their own recommendations or decisions on pricing or reimbursement.
Amendment 49 #
Proposal for a regulation Recital 17 (17) The time-frame for joint clinical assessments for medicinal products should, in as far as possible, be fixed by reference to the time-frame applicable to the completion of the central marketing authorisation procedure provided for under Regulation (EC) No 726/2004. Such coordination should ensure clinical assessments can effectively facilitate market access and contribute to the timely availability of innovative technologies for patients.
Amendment 50 #
Proposal for a regulation Recital 17 (17) The time-frame for joint clinical assessments for medicinal products should
Amendment 51 #
Proposal for a regulation Recital 18 Amendment 52 #
Proposal for a regulation Recital 18 (18) The establishment of a time-frame for the joint clinical assessments for medical devices should take into account the highly decentralised market access pathway for medical devices and the availability of appropriate evidence data required to carry out a joint clinical assessment. As the required evidence may only become available after a medical device has been placed on the market and in order to allow for the selection of medical devices for joint clinical assessment at an appropriate time, it should be possible for assessments of such devices to take place following market launch of medical devices and, if possible, in the presence of producers.
Amendment 53 #
Proposal for a regulation Recital 19 (19) In all cases the joint work carried out under this Regulation, in particular the joint clinical assessments, should produce high quality and timely results, and not delay or interfere with the
Amendment 54 #
Proposal for a regulation Recital 20 (20) In order to facilitate effective participation by health technology developers in joint clinical assessments, such developers should, in
Amendment 55 #
Proposal for a regulation Recital 21 Amendment 56 #
Proposal for a regulation Recital 21 (21) Joint clinical assessments and joint scientific consultations necessitate the sharing of confidential information between health technology developers and HTA authorities and bodies. In order to ensure the protection of such information, information provided to the Coordination Group in the framework of assessments and consultations should only be disclosed to a third party after a confidentiality agreement has been concluded with the notification of the technology developer that has provided the information. In addition, it is necessary for any information made public about the results of joint scientific consultations to be presented in an anonymised format with the redaction of any information of a commercially sensitive nature.
Amendment 57 #
Proposal for a regulation Recital 21 (21) Joint clinical assessments and joint scientific consultations necessitate the sharing of
Amendment 58 #
Proposal for a regulation Recital 21 a (new) (21 a) Joint scientific consultations should concern the clinical study design, the determination of best comparators based on the best medical practice in the interest of patients. The process should be transparent. Joint scientific consultations results should be made available to the general public.
Amendment 59 #
Proposal for a regulation Recital 25 (25) In order to ensure a uniform approach to the joint work provided for in this Regulation,
Amendment 60 #
Proposal for a regulation Recital 25 (25) In order to ensure a uniform approach to the joint work provided for in this Regulation, implementing powers should be conferred on the Commission to establish a common procedural and methodological framework for clinical assessments, procedures for joint clinical assessments and procedures for joint scientific consultations. Where appropriate, distinct rules should be developed for medicinal products and medical devices. In the development of such rules, the Commission should take into account the results of the work already undertaken in the EUnetHTA Joint Actions. It should also take into account initiatives on HTA funded through the Horizon 2020 research programme, as well as regional initiatives on HTA such as the Beneluxa and Valletta Declaration initiatives. Those powers should be exercised in accordance with Regulation (EU) No 182/2011 of the European Parliament and of the Council.13In developing such framework, the Commission should ensure that the assessments provide for an equal and high standard and focus on the aim of safe and patient-relevant health policies that seek to achieve best value. _________________ 13 Regulation (EU) No 182/2011 of the European Parliament and of the Council of 16 February 2011 laying down the rules and general principles concerning mechanisms for control by the Member States of the Commission's exercise of implementing powers (OJ L 55, 28.2.2011, p. 13).
Amendment 61 #
Proposal for a regulation Recital 25 (25) In order to ensure a uniform approach to the joint work provided for in this Regulation,
Amendment 62 #
Proposal for a regulation Recital 25 (25) In order to ensure a uniform approach to the joint work provided for in this Regulation, implementing powers should be conferred on the Commission to establish a common procedural and methodological framework for clinical assessments, procedures for joint clinical assessments and procedures for joint scientific consultations.
Amendment 63 #
Proposal for a regulation Recital 25 (25) In order to ensure a uniform approach to the joint work provided for in this Regulation, implementing powers should be conferred on the Commission to establish a common procedural and methodological framework for clinical assessments, procedures for joint clinical assessments and procedures for joint scientific consultations.
Amendment 64 #
Proposal for a regulation Recital 25 a (new) (25 a) The Commission, together with the Member States, should adapt the framework of joint clinical assessment to vaccines to take into account the preventive nature of vaccines that brings benefits to individuals and populations over a long time horizon, and should involve the appropriate national bodies in the joint clinical assessment of vaccines. The adaption of the framework should be completed by the end of the implementation period to ensure that it is ready to be used during the transition period.
Amendment 65 #
Proposal for a regulation Recital 26 (26) In order to ensure that this Regulation is fully operational and to adapt it to technical and scientific development, the
Amendment 66 #
Proposal for a regulation Recital 28 (28) In order to facilitate the joint work and the exchange of information between Member States on HTA, provision should be made for the establishment of an IT platform that contains appropriate databases and secure channels for communication. The Commission should also ensure a link between the IT platform and other data infrastructures relevant for the purposes of HTA such as registries of real world data. All relevant data should be made available to the public.
Amendment 67 #
Proposal for a regulation Recital 28 a (new) (28 a) The cooperation between Member States on HTA should be based on the principles of good governance, objectivity, independency and transparency. All Member States should have the right to make genuine commitments.
Amendment 68 #
Proposal for a regulation Recital 28 a (new) (28 a) Given the sensitive nature of health information, the confidential handling of data should be safeguarded at all times.
Amendment 69 #
Proposal for a regulation Recital 31 (31) In order to ensure that the support framework continues to be as efficient and cost-effective as possible, the Commission should report on the implementation of the provisions on the scope of the joint clinical assessments and on the functioning of the support framework no later than two years after the end of the transitional period.
Amendment 70 #
Proposal for a regulation Article 1 – paragraph 1 – introductory part 1. Taking into account the results of the work already undertaken in the EUnetHTA Joint Actions, this Regulation establishes:
Amendment 71 #
Proposal for a regulation Article 2 – paragraph 1 – point e (e) 'clinical assessment' means a compilation and
Amendment 72 #
Proposal for a regulation Article 2 – paragraph 1 – point g a (new) (g a) ´appraisal` means drawing conclusions on the added value of the technologies concerned as part of national appraisal processes which may consider clinical as well as non-clinical data and criteria.
Amendment 73 #
Proposal for a regulation Article 3 – paragraph 2 2. Member States shall designate their national authorities and bodies responsible for health technology assessment which inform decision-making at national level as members of the Coordination Group and its sub-groups and inform the Commission thereof and of any subsequent changes. Member States may designate more than one authority or body responsible for health technology assessment as members of the Coordination Group and one or more of its sub-groups. Each Member State may appoint to the Coordination Group at least one authority or body responsible with expertise in the field of medicinal products.
Amendment 74 #
Proposal for a regulation Article 3 – paragraph 3 3. The Coordination Group shall act by consensus, or, where n
Amendment 75 #
Proposal for a regulation Article 3 – paragraph 3 3. The Coordination Group shall act by consensus, or, where necessary, vote by
Amendment 76 #
Proposal for a regulation Article 3 – paragraph 3 3. The Coordination Group shall act by consensus, or, where necessary, vote by
Amendment 77 #
Proposal for a regulation Article 3 – paragraph 4 4. Meetings of the Coordination Group shall be co-chaired by the Commission without the right to vote and a co-chair elected from the members of the group for a set term to be determined in its rules of procedure.
Amendment 78 #
Proposal for a regulation Article 3 – paragraph 6 6. Members of the Coordination Group, and their appointed representatives shall respect the principles of independence, impartiality, and confidentiality. Transparency and publicity of the process is essential. In this connection, all clinical data being evaluated shall have the highest level of transparency and publicity in order to gain confidence in the system. In case there is confidential data for commercial reasons, the confidentiality needs to be clearly defined and justified and the confidential data well delimitated.
Amendment 79 #
Proposal for a regulation Article 3 – paragraph 8 – point a a (new) (a a) adopt rules on conflicts of interest for the functioning of the coordination groups and the conduction of joint clinical assessments and joint scientific consultations.
Amendment 80 #
Proposal for a regulation Article 3 – paragraph 8 – point d (d) ensure appropriate and regular involvement of stakeholders in its work;
Amendment 81 #
Proposal for a regulation Article 4 – paragraph 3 – point c (c) consult the Commission on the draft annual work programme
Amendment 82 #
Proposal for a regulation Article 4 – paragraph 3 – point c – point i (new) i) consult civil society organisations, patient associations, social partners, consumer organisations, healthcare professionals and non-governmental organisations in the field of health technology assessment.
Amendment 83 #
Proposal for a regulation Article 5 – paragraph 1 – point b Amendment 84 #
Proposal for a regulation Article 5 – paragraph 1 – point b a (new) (b a) other medical devices considered to be major innovations or with a potentially significant impact on national health care systems.
Amendment 85 #
Proposal for a regulation Article 5 – paragraph 1 – point c Amendment 86 #
Proposal for a regulation Article 5 – paragraph 2 Amendment 87 #
Proposal for a regulation Article 5 – paragraph 2 – introductory part 2. The Coordination Group shall select the medical devices referred to in paragraph 1 points (b) and (c) for joint clinical assessment
Amendment 88 #
Proposal for a regulation Article 5 – paragraph 2 – introductory part 2. The Coordination Group shall select the medical devices referred to in paragraph 1 points (b), (ba) and (c) for joint clinical assessment based on the following criteria:
Amendment 89 #
Proposal for a regulation Article 5 – paragraph 2 – point e – point i (new) i) points arising from the annual meeting of the stakeholder network;
Amendment 90 #
Proposal for a regulation Article 5 a (new) Article 5 a Methodological standards 1. Joint clinical assessments should be based on standards of evidence-based medicine. The added therapeutic value should be demonstrated on patient- relevant end points: mortality, morbidity, quality of life, according to the situation. 2. The manufacturers shall provide all data from all sponsored studies in the indication under assessment. In case of non-compliance to provide full data, the joint assessment shall be interrupted or even discontinued. The names of those manufactories who failed to provide all the necessary data shall be made public.
Amendment 91 #
Proposal for a regulation Article 5 b (new) Article 5 b Conduct of comparative trials against standard treatment 1. Health technology developers shall conduct at least one randomized clinical trial comparing their new drug with an active comparator considered among the best current proven interventions at the time the trial was designed (standard treatment), or the most common intervention when no standard treatment exists. The developer is expected to comply with established guidelines on development of products and to take into account the current medical knowledge to establish the best comparative alternative. 2. Full results of comparative trials, including raw and individual patient data (clinical study reports), shall be made available at the time of applications for a marketing authorization and shall be included in HTA applications. As soon as the joint clinical assessment is finalized, all information and datas shall be made publicly available as provided for by Regulation 1049/2001. 3.If the developer obtained scientific advice on data and evidence requirements, and did not follow the advice, the developer shall be asked to justify the deviation from the advice given.
Amendment 92 #
Proposal for a regulation Article 6 – paragraph 1 – subparagraph 2 The joint clinical assessment report shall be accompanied by a summary report and they shall be prepared in accordance with the requirements in this Article
Amendment 93 #
Proposal for a regulation Article 6 – paragraph 2 2. The designated sub-group shall request relevant health technology developers to submit documentation containing the information, data and evidence necessary for the joint clinical assessment. In the interests of transparency, the relationship between evaluators and technology developers must be independent. The evaluators must have guaranteed their independence in the development of their work, without there being neither conditionalities nor interference from the technology developers in the evaluation process. Developers of technologies can be consulted but never participate in the evaluation.
Amendment 94 #
Proposal for a regulation Article 6 – paragraph 2 2. The designated sub-group shall request relevant health technology developers to submit comprehensive documentation containing the information, all available data and evidence, including both negative and positive results as well as studies in which the technology has been used, necessary for the joint clinical assessment
Amendment 95 #
Proposal for a regulation Article 6 – paragraph 2 2. The designated sub-group shall request relevant health technology developers to submit documentation containing the information, data and evidence necessary for the joint clinical assessment. The relationship between evaluators and health technology developers must be independent and impartial. Developers of health technologies can be consulted but never participate actively in the evaluation process.
Amendment 96 #
Proposal for a regulation Article 6 – paragraph 2 a (new) 2 a. The designated sub-group shall request, in addition to the data referred to in paragraph 2, data from relevant sources, such as patient registries, databases or European Reference Networks, where that data is deemed necessary to complete the information provided by the health technology developers and to perform a more accurate clinical assessment of the health technology.
Amendment 97 #
Proposal for a regulation Article 6 – paragraph 3 3. The designated sub-group shall appoint, from among its members, an assessor and a co-assessor from different Member State to conduct the joint clinical assessment. The appointments shall take into account the scientific expertise necessary for the assessment.
Amendment 98 #
Proposal for a regulation Article 6 – paragraph 5 – point a (a) a
Amendment 99 #
Proposal for a regulation Article 6 – paragraph 5 a (new) 5 a. The joint clinical assessment report shall not refer to non-clinical assessment domains nor shall it draw conclusions on the added value of the technologies concerned which remain part of national appraisal processes.
source: 623.737
2018/06/15
ENVI
192 amendments...
Amendment 407 #
Proposal for a regulation Article 7 – paragraph 1 1. Where the Commission considers that there are no legal obstacles to the inclusion of the approved joint clinical assessment report and summary report
Amendment 408 #
Proposal for a regulation Article 7 – paragraph 1 1. Where the Commission considers that the approved joint clinical assessment report and summary report comply with the
Amendment 409 #
Proposal for a regulation Article 7 – paragraph 1 1. Where the Commission considers that the approved joint clinical assessment report and summary report comply with the
Amendment 410 #
Proposal for a regulation Article 7 – paragraph 1 1. Where the Commission considers that the approved joint clinical assessment report and summary report comply with the
Amendment 411 #
Proposal for a regulation Article 7 – paragraph 1 a (new) 1a. All of the necessary steps leading to the inclusion of the name of the health technology which has been the subject of the approved report and summary report shall be completed by the time of the publication of the Commission decision granting marketing authorisation.
Amendment 412 #
Proposal for a regulation Article 7 – paragraph 2 Amendment 413 #
Proposal for a regulation Article 7 – paragraph 2 2. Where, within 30 days of receipt of the approved joint clinical assessment report and the summary report, the Commission concludes that the approved joint clinical assessment report and summary report do not comply with the
Amendment 414 #
Proposal for a regulation Article 7 – paragraph 2 2. Where, within 30 days of receipt of the approved joint clinical assessment report and the summary report, the Commission concludes that the approved joint clinical assessment report and summary report do not comply with the
Amendment 415 #
Proposal for a regulation Article 7 – paragraph 2 2. Where, within 30 days of receipt of
Amendment 416 #
Proposal for a regulation Article 7 – paragraph 3 Amendment 417 #
Proposal for a regulation Article 7 – paragraph 3 Amendment 418 #
Proposal for a regulation Article 7 – paragraph 4 Amendment 419 #
Proposal for a regulation Article 7 – paragraph 4 Amendment 420 #
Proposal for a regulation Article 7 – paragraph 4 4. Following the submission of the modified approved joint clinical assessment report and summary report, and where the Commission considers that the modified approved joint clinical
Amendment 421 #
Proposal for a regulation Article 7 – paragraph 4 4. Following the submission of the modified approved joint clinical assessment report and summary report, and where the Commission considers that the modified approved joint clinical assessment report and summary report comply with the
Amendment 422 #
Proposal for a regulation Article 7 – paragraph 5 Amendment 423 #
Proposal for a regulation Article 7 – paragraph 5 Amendment 424 #
Proposal for a regulation Article 7 – paragraph 5 5. If the Commission concludes that the modified approved joint clinical assessment report and summary report do not comply with the
Amendment 425 #
Proposal for a regulation Article 7 – paragraph 5 5. If the Commission concludes that the modified approved joint clinical assessment report and summary report do not comply with the
Amendment 426 #
Proposal for a regulation Article 7 – paragraph 6 6. For those health technologies included on the List of Assessed Health Technologies, the Commission shall publish the approved joint clinical assessment report and summary report on the IT platform referred to in Article 27 and make them available to the submitting health technology developer at the latest
Amendment 427 #
Proposal for a regulation Article 7 – paragraph 6 a (new) 6a. All relevant data and information shall be available to the public in a user- friendly and easy-readable manner.
Amendment 428 #
Proposal for a regulation Article 8 – paragraph 1 – introductory part 1. For the health technologies included on the List of Assessed Health Technologies or in respect of which a joint clinical assessment has been initiated, Member States shall:
Amendment 429 #
Proposal for a regulation Article 8 – paragraph 1 – point a Amendment 430 #
Proposal for a regulation Article 8 – paragraph 1 – point a (a)
Amendment 431 #
Proposal for a regulation Article 8 – paragraph 1 – point a (a) not carry out
Amendment 432 #
Proposal for a regulation Article 8 – paragraph 1 – point a (a) not carry out a clinical assessment or an equivalent assessment process on a health technology included in the List of Assessed Health Technologies or for which a joint clinical assessment has been initiated. According to national needs, Member States shall have the right to complement the report with additional clinical evidence;
Amendment 433 #
Proposal for a regulation Article 8 – paragraph 1 – point a a (new) (aa) This shall not prevent the Member States from complementing the joint clinical assessment with clinical assessments comparing the technology against a comparator which represents the best available standard of care in this Member State or assessing the technology in a different care context how the technology is applied which, despite the Member States request during the scoping phase, will not form part of the joint clinical assessment and which is necessary to complete the health technology assessment in that Member State. Any such measure should be justified, necessary and proportionate to achieving this aim.
Amendment 434 #
Proposal for a regulation Article 8 – paragraph 1 – point a b (new) (ab) The Member State shall notify the Commission and the Coordination Group of their intention to complement the joint clinical assessment together with a justification for doing so no later than 2 weeks after the Coordination Group has laid down the specific requirements for the joint assessment of the specific technology.
Amendment 435 #
Proposal for a regulation Article 8 – paragraph 1 – point b (b)
Amendment 436 #
Proposal for a regulation Article 8 – paragraph 1 a (new) 1a. This shall not prevent the Member States from complementing the joint clinical assessment with clinical assessments comparing the technology against a comparator which represents the best available evidence based standard of care in this Member State which, despite the Member States request during the scoping face, will not form part of the joint clinical assessment and which is necessary to complete the health technology assessment in that Member State. Any such measure should be justified, necessary and proportionate to achieving this aim. Any national assessment complementing the joint clinical assessment should follow the methodology established in accordance with Article 22. Member States shall notify the Commission and the Coordination Group of their intention to complement the joint clinical assessment together with a justification for doing so no later than 2 weeks after the Coordination Group has laid down the specific requirements for the joint assessment of the specific technology.
Amendment 437 #
Proposal for a regulation Article 8 – paragraph 1 a (new) 1a. Paragraph 1(b) shall not prevent Member States from carrying out assessments on the added clinical value of the technologies concerned as part of national or regional appraisal processes which may consider clinical as well as non-clinical data and evidence specific to the Member State concerned which did not form part of the joint clinical assessment and which are necessary to complete the general assessment of health technology, provided these additional requirements do not delay patient access to these technologies.
Amendment 438 #
Proposal for a regulation Article 8 – paragraph 1 a (new) 1a. Paragraph 1 shall not prevent Member States from carrying out complementary assessments as part of their own context-specific appraisal processes, without unnecessarily duplicating the work done at EU level.
Amendment 439 #
Proposal for a regulation Article 8 – paragraph 2 2. Member States shall notify the Commission of the outcome of a health technology assessment on a health technology which has been subject to a joint clinical assessment within 30 days from its completion. That notification shall be accompanied by information on how the conclusions of the joint clinical assessment report have been applied in the overall health technology assessment. The final report must be made publicly available. The Commission shall facilitate the exchange of this information between Member States through the IT platform referred to in Article 27.
Amendment 440 #
Proposal for a regulation Article 8 – paragraph 2 2. Member States shall notify the Commission of the outcome of a health technology assessment on a health technology which has been subject to a joint clinical assessment within 30 days from
Amendment 441 #
Proposal for a regulation Article 9 – paragraph 1 – point b a (new) (ba) the health technology developer requests an update on the grounds that additional evidence is made available for which the Coordination Group would need to reconsider the conclusions of the initial assessment.
Amendment 442 #
Proposal for a regulation Article 9 – paragraph 1 – point b a (new) (ba) at the request of a Member State that considers that there is new clinical evidence.
Amendment 443 #
Proposal for a regulation Article 9 – paragraph 2 2. The Coordination Group may carry out updates of joint clinical assessments where requested by one or more of its members. Updates are requested when new information has been published or made available which was not available at the time of the initial joint report. When an update of the joint report is decided, the member who proposed it can update the report and propose it for adoption by other Member States through mutual recognition. When updating the report, the Member State will apply the methods and standards as defined by the Coordination Group. In case Member States disagree with the update and it cannot be adopted by consensus, the case will be referred to the Coordination Group that will decide whether to carry out an update based on this new information. When an update is approved by mutual recognition or after the Coordination Group has carried out an update, the joint report is considered updated.
Amendment 444 #
Proposal for a regulation Article 9 – paragraph 2 2. The Coordination Group may carry out updates of joint clinical assessments where requested by one or more of its members. Updates are requested when new information has been published or made available which was not available at the time of the initial joint report. When an update of the joint report is decided, the member who proposed it can update the report and propose it for adoption by other Member States by mutual recognition. When updating the report, the Member State will apply the methods and standards as defined by the Coordination Group. In case Member States disagree with the update and it cannot be adopted by consensus, the case will be referred to the Coordination Group that will decide whether to carry out an update based on this new information. When an update is approved by mutual recognition or after the Coordination Group has carried out an update, the joint report is considered updated.
Amendment 445 #
Proposal for a regulation Article 9 – paragraph 2 a (new) 2a. Member States may update the clinical assessments for their own use taking into account their local conditions. If a Member States decides to take such a decision, it shall inform the Coordination Group. The Coordination Group may oppose within the period of 3 months only if a majority of three fourth votes against it.
Amendment 446 #
Proposal for a regulation Article 9 a (new) Article 9a 1. The Coordination Group shall consider carrying out an update of a joint clinical assessment at the moment of the renewal of the marketing authorisation after five years pursuant to Article 14 of Regulation (EU)726/2004. 2. Should additional relevant evidence become available prior to the renewal of the marketing authorisation, the Coordination Group shall also consider carrying out an update of the joint clinical assessment.
Amendment 447 #
Proposal for a regulation Article 11 – paragraph 1 – introductory part 1. The Co
Amendment 448 #
Proposal for a regulation Article 11 – paragraph 1 – point c (c) determining the detailed procedural steps, including for appeal mechanisms for health technology developers, and their timing, and the overall duration of joint clinical assessments;
Amendment 449 #
Proposal for a regulation Article 11 – paragraph 1 – point c (c) determining the detailed procedural steps and their timing
Amendment 450 #
Proposal for a regulation Article 11 – paragraph 1 – point c (c) determining the detailed procedural steps and their timing
Amendment 451 #
Proposal for a regulation Article 11 – paragraph 1 – point f Amendment 452 #
Proposal for a regulation Article 11 – paragraph 1 – point f a (new) (fa) mechanisms for the appeals on the joint clinical assessment.
Amendment 453 #
Proposal for a regulation Article 11 – paragraph 1 – point f a (new) (fa) a mandatory stakeholder participation with hearings and the opportunity to address written statements at the beginning of the assessment and before the draft report is finalised, including all relevant health technology developers, their associations on national and European level, all relevant medical societies on national and European level and patient organisations on national and European level.
Amendment 454 #
Proposal for a regulation Article 11 – paragraph 1 – point f a (new) (fa) mechanisms for the appeals on the joint clinical assessment.
Amendment 455 #
Proposal for a regulation Article 11 – paragraph 2 Amendment 456 #
Proposal for a regulation Article 12 – paragraph 1 – subparagraph 1 Health technology developers may request a joint scientific consultation with the Coordination Group for the purposes of obtaining scientific advice concerning
Amendment 457 #
Proposal for a regulation Article 12 – paragraph 3 a (new) 3a. Article 12 (2) and 12 (3) shall not apply for medicinal products.
Amendment 458 #
Proposal for a regulation Article 13 – title Amendment 459 #
Proposal for a regulation Article 13 – paragraph 1 – subparagraph 1 Following the acceptance of a request for a joint scientific consultation in accordance with Article 12 and on the basis of its annual work programme, the Coordination Group shall designate a sub-group to oversee
Amendment 460 #
Proposal for a regulation Article 13 – paragraph 1 – subparagraph 2 Amendment 461 #
Proposal for a regulation Article 13 – paragraph 2 2. The designated sub-group shall request the health technology developer to submit the documentation containing the information, data and evidence necessary for the joint scientific consultation. In light of the challenges related to conducting a clinical assessment for orphan medicines due to the limited number of patients enrolled in clinical trials and/or the lack of a comparator, a tailored clinical assessment pathway should be developed for this category of treatments.
Amendment 462 #
Proposal for a regulation Article 13 – paragraph 2 2. The designated sub-group shall request the health technology developer to submit the documentation containing the information, data and evidence necessary for the joint scientific consultation. A joint meeting shall be scheduled on this basis, the agenda to be agreed between the designated sub-group and the health technology developer concerned.
Amendment 463 #
Proposal for a regulation Article 13 – paragraph 2 2. The designated sub-group shall request the health technology developer to submit the
Amendment 464 #
Proposal for a regulation Article 13 – paragraph 3 Amendment 465 #
Proposal for a regulation Article 13 – paragraph 4 Amendment 466 #
Proposal for a regulation Article 13 – paragraph 5 Amendment 467 #
Proposal for a regulation Article 13 – paragraph 6 Amendment 468 #
Proposal for a regulation Article 13 – paragraph 7 Amendment 469 #
Proposal for a regulation Article 13 – paragraph 7 7. The assessor shall p
Amendment 470 #
Proposal for a regulation Article 13 – paragraph 8 8. The designated sub-group shall ensure that stakeholders, including patients, consumer organisations and clinical experts are given an opportunity to provide comments during the preparation of the draft joint scientific consultation report and set a time-frame in which they may submit comments.
Amendment 471 #
Proposal for a regulation Article 13 – paragraph 8 8. The designated sub-group shall ensure that stakeholders, including
Amendment 472 #
Proposal for a regulation Article 13 – paragraph 8 8. The designated sub-group shall ensure that stakeholders, including patients
Amendment 473 #
Proposal for a regulation Article 13 – paragraph 8 8. The designated sub-group shall ensure that stakeholders, including patients, consumer organisations and clinical experts are given an opportunity to provide comments during
Amendment 474 #
Proposal for a regulation Article 13 – paragraph 8 8.
Amendment 475 #
Proposal for a regulation Article 13 – paragraph 9 9. Following receipt and consideration of any comments provided in accordance with paragraphs 6, 7 and 8, the assessor, with the assistance of the co-assessor, shall finalise the draft joint scientific consultation report and submit the draft report to the designated sub-group for comments. All comments, which shall be public and duly answered in the scientific consultation report, shall be published on the IT platform referred to in Article 27 following finalisation of the joint clinical assessment of the health technology for which the consultation was sought.
Amendment 476 #
Proposal for a regulation Article 13 – paragraph 9 9. Following receipt and consideration of any information and comments provided in accordance with paragraphs
Amendment 477 #
Proposal for a regulation Article 13 – paragraph 10 Amendment 478 #
Proposal for a regulation Article 13 – paragraph 10 10. Where the joint scientific consultation is carried out in parallel with scientific advice given by the European Medicines Agency, the assessor shall seek to coordinate with the Agency
Amendment 479 #
Proposal for a regulation Article 13 – paragraph 10 10. Where the joint scientific consultation is carried out in parallel with
Amendment 480 #
Proposal for a regulation Article 13 – paragraph 10 10. Where the joint scientific consultation is carried out in parallel with scientific advice given by the European Medicines Agency, the assessor shall seek to coordinate with the
Amendment 481 #
Proposal for a regulation Article 13 – paragraph 11 Amendment 482 #
Proposal for a regulation Article 13 – paragraph 12 12. The Coordination Group shall approve the final joint scientific consultation report, wherever possible by consensus or, where necessary, by a
Amendment 483 #
Proposal for a regulation Article 13 – paragraph 12 12. The Coordination Group shall approve the final joint scientific consultation report, wherever possible by consensus, or, where n
Amendment 484 #
Proposal for a regulation Article 13 – paragraph 12 12. The Coordination Group shall approve the final joint scientific consultation report, wherever possible by consensus or, where necessary, by a
Amendment 485 #
Proposal for a regulation Article 13 – paragraph 12 12. The Coordination Group shall approve the final joint scientific consultation report, wherever possible by consensus or, where necessary, by a
Amendment 486 #
Proposal for a regulation Article 13 – paragraph 12 12. The Coordination Group shall approve the final joint scientific consultation report, wherever possible by consensus or, where necessary, by
Amendment 487 #
Proposal for a regulation Article 13 – paragraph 12 a (new) 12a. Members of the Coordination Group participating in the elaboration of joint scientific consultations for a health technology shall not also participate in the joint clinical assessment of the same health technology.
Amendment 488 #
Proposal for a regulation Article 13 – paragraph 12 a (new) 12a. Delegates and experts participating in joint scientific consultations for a given health technology shall not participate in the joint clinical assessment of this technology.
Amendment 489 #
Proposal for a regulation Article 14 – paragraph 1 1. The Coordination Group shall communicate the approved joint scientific consultation report to the requesting health technology developer at the
Amendment 490 #
Proposal for a regulation Article 14 – paragraph 2 2. The Coordination Group shall include
Amendment 491 #
Proposal for a regulation Article 14 – paragraph 2 2. The Coordination Group shall include
Amendment 492 #
Proposal for a regulation Article 14 – paragraph 2 2. The Coordination Group shall
Amendment 493 #
Proposal for a regulation Article 14 – paragraph 3 3. Member States
Amendment 494 #
Proposal for a regulation Article 16 – paragraph 1 – introductory part 1. The Co
Amendment 495 #
Proposal for a regulation Article 16 – paragraph 1 – point d (d) the consultation of
Amendment 496 #
Proposal for a regulation Article 16 – paragraph 1 – point d (d) the consultation of patients, consumer organisations, clinical experts and other relevant stakeholders;
Amendment 497 #
Proposal for a regulation Article 16 – paragraph 1 – point d (d) the consultation of patients, c
Amendment 498 #
Proposal for a regulation Article 16 – paragraph 1 – point f Amendment 499 #
Proposal for a regulation Article 16 – paragraph 2 Amendment 500 #
Proposal for a regulation Article 17 – paragraph 1 – introductory part The Co
Amendment 501 #
Proposal for a regulation Article 17 – paragraph 1 – point b (b) the rules for determining the stakeholders to be consulted for the purpose of this Section, including rules on conflicts of interest. Declarations of interest shall be made publicly available for all stakeholders and experts consulted. Stakeholders and experts with conflicts of interest shall not participate in the process.
Amendment 502 #
Proposal for a regulation Article 17 – paragraph 1 – point b (b) the rules for determining the stakeholders to be consulted for the purpose of this Section. Declarations on conflict of interest shall be made publicly available for all stakeholders and those with conflicts of interest shall not participate in the process.
Amendment 503 #
Proposal for a regulation Article 17 – paragraph 1 – point b Amendment 504 #
Proposal for a regulation Article 18 – paragraph 2 – introductory part 2. In the preparation of the study, the Coordination Group shall equally consult:
Amendment 505 #
Proposal for a regulation Article 18 – paragraph 2 – point b (b) patient and consumer organisations;
Amendment 506 #
Proposal for a regulation Article 18 – paragraph 2 – point b (b) patient and consumer organisations;
Amendment 507 #
Proposal for a regulation Article 18 – paragraph 2 – point e Amendment 508 #
Proposal for a regulation Article 18 – paragraph 3 – subparagraph 1 (new) When preparing the study, the Coordination Group shall ensure that commercially confidential information provided by the health technology developer is adequately protected. To this end, the Coordination Group shall give the health technology developer an opportunity to submit comments with respect to the contents of the study and shall take due account of those comments.
Amendment 509 #
Proposal for a regulation Article 19 – paragraph 1 – introductory part 1.
Amendment 510 #
Proposal for a regulation Article 19 – paragraph 1 – introductory part 1. The Commission shall support cooperation and the exchange of scientific information among Member States
Amendment 511 #
Proposal for a regulation Article 19 – paragraph 1 – point a Amendment 512 #
Proposal for a regulation Article 19 – paragraph 1 – point b Amendment 513 #
Proposal for a regulation Article 19 – paragraph 1 – point b (b) collaborative assessments on medical devices
Amendment 514 #
Proposal for a regulation Article 19 – paragraph 1 – point c Amendment 515 #
Proposal for a regulation Article 19 – paragraph 1 – point d Amendment 516 #
Proposal for a regulation Article 19 – paragraph 1 – subparagraph 1 (new) Groups of Member States which share a common need identify, define and conduct collaborative clinical assessments on medical devices and in vitro diagnostics, as defined by Article 19(1) (b). The composition of these groups can vary.
Amendment 517 #
Proposal for a regulation Article 19 – paragraph 1 – point d a (new) (da) the tightening of the rules on clinical evidence, including a coordinated procedure for the authorisation of multi- centre clinical research;
Amendment 518 #
Proposal for a regulation Article 19 – paragraph 2 2.
Amendment 519 #
Proposal for a regulation Article 19 – paragraph 3 Amendment 520 #
Proposal for a regulation Article 19 – paragraph 3 3. The cooperation referred to in paragraph 1 points (b) and (c) may be carried out using the procedural rules established in accordance with Article 11 and the common rules established
Amendment 521 #
Proposal for a regulation Article 19 – paragraph 4 Amendment 522 #
Proposal for a regulation Article 20 – paragraph 1 – introductory part The common procedural rules and methodology established in accordance with Article 22 and the requirements established in accordance with Article 23 shall apply to
Amendment 523 #
Proposal for a regulation Article 20 – paragraph 1 – introductory part The common procedural rules and methodology established in accordance with Article 22 and the requirements established in accordance with Article 23 shall apply to
Amendment 524 #
Proposal for a regulation Article 20 – paragraph 1 – introductory part The common procedural rules and methodology established
Amendment 525 #
Proposal for a regulation Article 20 – paragraph 1 – point a Amendment 526 #
Proposal for a regulation Article 20 – paragraph 1 – point a Amendment 527 #
Proposal for a regulation Article 20 – paragraph 1 – point b Amendment 528 #
Proposal for a regulation Article 20 – paragraph 1 – point b Amendment 529 #
Proposal for a regulation Article 20 – paragraph 1 – point b Amendment 530 #
Proposal for a regulation Article 21 – paragraph 1 1. Where a clinical assessment is carried out by a Member State, that Member State shall provide the Commission with the clinical assessment report and summary report at the latest 30 working days after the completion of the health technology assessment. The summary report shall be written in an understandable manner for the general public.
Amendment 531 #
Proposal for a regulation Article 22 – paragraph 1 – introductory part 1. Taking into account the results of the work already undertaken in the EUnetHTA Joint Actions, the Commission shall adopt implementing acts concerning:
Amendment 532 #
Proposal for a regulation Article 22 – paragraph 1 – introductory part 1.
Amendment 533 #
Proposal for a regulation Article 22 – paragraph 1 – introductory part 1. The Co
Amendment 534 #
Proposal for a regulation Article 22 – paragraph 1 – point a – point ii (ii) the mechanisms for the interaction between health technology bodies and health technology developers during clinical assessments, subject to the provisions of the previous article;
Amendment 535 #
Proposal for a regulation Article 22 – paragraph 1 – point a – point iii (iii) the consultation of patients, c
Amendment 536 #
Proposal for a regulation Article 22 – paragraph 1 – point a – point iii (iii) the consultation of patients, consumer organisations, clinical experts
Amendment 537 #
Proposal for a regulation Article 22 – paragraph 1 – point a – point iii (iii) the consultation of patients, clinical experts, and other stakeholders in clinical assessments and the duly justified replies.
Amendment 538 #
Proposal for a regulation Article 22 – paragraph 1 – point a – point iii (iii) the consultation of patients, clinical experts, and other stakeholders in clinical assessments, subject to the provisions of the previous article.
Amendment 539 #
Proposal for a regulation Article 22 – paragraph 1 – point a – point iii (iii) the consultation of patients and patient organisations, clinical experts, and other stakeholders in clinical assessments.
Amendment 540 #
Proposal for a regulation Article 22 – paragraph 1 – point a – point iii (iii) the consultation of
Amendment 541 #
Proposal for a regulation Article 22 – paragraph 1 – point a – point iii a (new) (iiia) ensuring that the assessments of medical devices can take place at the appropriate point in time after market launch, allowing for the use of clinical effectiveness data, including real world data. The appropriate time point shall be identified in cooperation with relevant stakeholders.
Amendment 542 #
Proposal for a regulation Article 22 – paragraph 1 – point b (b) methodologies used to formulate the contents and design of clinical assessments. Common methods as well as data requirements and outcome measures shall take into account the specificities of medical devices and in vitro diagnostics.
Amendment 543 #
Proposal for a regulation Article 22 – paragraph 1 – point b (b) methodologies to be consistently used to formulate the contents and design of clinical assessments.
Amendment 544 #
Proposal for a regulation Article 22 – paragraph 1 – point b – subpoint 1 (new) The health technology developer shall conduct at least one randomized controlled clinical trial, comparing its health technology in terms of clinically relevant outcomes with an active comparator considered among the best current proven intervention at the time the trial was designed (standard treatment), or the most common intervention when no standard treatment exists. The technology developer shall provide the data and results of conducted comparative trials in the documentation dossier submitted for the joint clinical assessment.
Amendment 545 #
Proposal for a regulation Article 22 – paragraph 1 – point b a (new) (ba) a sanctions mechanism in the event of non-compliance by the technology developer with the requirements concerning the available information to be provided.
Amendment 546 #
Proposal for a regulation Article 22 – paragraph 1 a (new) Amendment 547 #
Proposal for a regulation Article 22 – paragraph 1 a (new) 1a. Procedural rules and methodologies referred to in paragraph 1 shall follow the output of the EUnetHTA Joint Actions, be developed and agreed between all stakeholders in a transparent manner, updated periodically and publicly available.
Amendment 548 #
Proposal for a regulation Article 22 – paragraph 1 b (new) 1b. The methodology mentioned in paragraph 1(b) shall also take into account : – the lifelong effect of a vaccine through appropriate time horizon of the analyses; – indirect effects such as herd immunity; – elements independent from the vaccine as such, for example coverage rates linked to programmes.
Amendment 549 #
Proposal for a regulation Article 23 – paragraph 1 – introductory part The Co
Amendment 550 #
Proposal for a regulation Article 23 – paragraph 1 – point a – introductory part (a) the
Amendment 551 #
Proposal for a regulation Article 24 – paragraph 1 1. The financing of the work of the Coordination Group and its sub-groups and activities in support of that work involving its cooperation with the Commission, with the European Medicines Agency, and with the stakeholder network referred to in Article 26 shall be ensured by the Union. The Union's financial assistance to the activities under this Regulation shall be implemented in accordance with Regulation (EU, Euratom) No 966/2012 of the European Parliament and of the Council.18 The joint work on HTA shall be conducted without the direct or indirect funding by developers of health technologies. __________________ 18 Regulation (EU, Euratom) No 966/2012 of the European Parliament and of the Council of 25 October 2012 on the financial rules applicable to the general budget of the Union and repealing Council Regulation (EC, Euratom) No 1605/2002 (OJ L 298, 26.10.2012, p. 1).
Amendment 552 #
Proposal for a regulation Article 24 – paragraph 2 2. The funding referred to in paragraph 1 shall include funding for the participation of Member States' designated health technology authorities and bodies in support of the work on joint clinical assessments and joint scientific consultations, as well as projects for training and capacity building to support exchange of experience and sharing of good practices between national authorities and experts. Assessor and co- assessors shall be entitled to a special allowance compensating them for their work on joint clinical assessments and joint scientific consultations in accordance with internal Commission provisions.
Amendment 553 #
Proposal for a regulation Article 24 – paragraph 2 2. The funding referred to in paragraph 1 shall include funding for the participation of Member States' designated health technology authorities and bodies in support of the work on joint clinical assessments and joint scientific consultations, and to enable the participation of patient and consumer representatives in the stakeholder network, joint clinical assessments and scientific consultations. Assessor and co- assessors shall be entitled to a special allowance
Amendment 554 #
Proposal for a regulation Article 24 – paragraph 2 a (new) 2a. The Union shall ensure stable and permanent public funding under the multiannual financial framework.
Amendment 555 #
Proposal for a regulation Article 25 – paragraph 1 – point a (a) host
Amendment 556 #
Proposal for a regulation Article 25 – paragraph 1 – point b (b) provide the secretariat for the Coordination Group and provide administrative
Amendment 557 #
Proposal for a regulation Article 25 – paragraph 1 – point d (d) verify that the work of the Coordination Group is carried out in an independent and transparent manner, according to the rules of procedure established;
Amendment 558 #
Proposal for a regulation Article 25 – paragraph 1 – point e (e) facilitate cooperation with the European Medicines Agency on the joint work on medicinal products including the sharing of
Amendment 559 #
Proposal for a regulation Article 25 – paragraph 1 – point f Amendment 560 #
Proposal for a regulation Article 25 – paragraph 1 – point f (f) facilitate cooperation with the relevant Union level bodies on the joint work on medical devices including the sharing of
Amendment 561 #
Proposal for a regulation Article 26 – paragraph 1 1. The Commission shall establish a stakeholder network through an open call for applications and a selection of suitable stakeholder organisations based on selection criteria established in the open call for applications. The organisations to be addressed by the call and represented within the stakeholder network shall be civil society organisations, patient associations, social partners, consumer organisations, healthcare professionals and non- governmental organisations in the field of health technology assessment.
Amendment 562 #
Proposal for a regulation Article 26 – paragraph 1 1. The Commission shall establish a stakeholder network through an open call for applications and a selection of suitable stakeholder organisations based on selection criteria established in the open call for applications. The organisations to be addressed by the call shall be legally established European umbrella patient associations representing different disease areas, consumer organisations, non- governmental organisations in the field of health and healthcare professionals.
Amendment 563 #
Proposal for a regulation Article 26 – paragraph 1 1. The Commission shall establish a stakeholder network through an open call for applications and a selection of suitable stakeholder organisations based on selection criteria, agreed by the Coordination Group, established in the open call for applications. Members of the stakeholder network shall be not-for- profit organisations representing non- commercial entities.
Amendment 564 #
Proposal for a regulation Article 26 – paragraph 1 1. The Commission shall establish a stakeholder network through an open call for applications and a selection of suitable stakeholder organisations based on selection criteria established in the open call for applications. Best practices in preventing conflict of interest shall apply to the selection of members of the stakeholder network.
Amendment 565 #
Proposal for a regulation Article 26 – paragraph 1 1. The Commission shall establish a stakeholder network through an open call for applications and a selection of suitable stakeholder organisations, including patient organisations, based on selection criteria established in the open call for applications.
Amendment 566 #
Proposal for a regulation Article 26 – paragraph 1 1. The Commission shall establish a stakeholder network through an open call for applications and a selection of suitable stakeholder organisations based on selection criteria
Amendment 567 #
Proposal for a regulation Article 26 – paragraph 2 2. The Commission shall publish the list of stakeholder organisations included in the stakeholder network, which shall be not- for-profit organisations, with no conflict of interest.
Amendment 568 #
Proposal for a regulation Article 26 – paragraph 3 – introductory part 3. The Commission shall organise
Amendment 569 #
Proposal for a regulation Article 26 – paragraph 3 – introductory part 3. The Commission shall organise ad- hoc meetings between the stakeholder
Amendment 570 #
Proposal for a regulation Article 26 – paragraph 3 – introductory part 3. The Commission shall organise
Amendment 571 #
Proposal for a regulation Article 26 – paragraph 3 – introductory part 3. The Commission shall organise
Amendment 572 #
Proposal for a regulation Article 26 – paragraph 3 – introductory part 3. The Commission shall organise
Amendment 573 #
Proposal for a regulation Article 26 – paragraph 3 – point b a (new) (ba) seek input into the annual work programme and the annual study prepared by the Coordination Group;
Amendment 574 #
Proposal for a regulation Article 26 – paragraph 4 4. On the request of the Coordination Group, the Commission shall invite patients and clinical experts nominated by the stakeholder network to
Amendment 575 #
Proposal for a regulation Article 26 – paragraph 4 4. On the request of the Coordination Group, the Commission shall invite patients, healthcare professionals and clinical experts nominated by the stakeholder network to attend meetings of the Coordination Group as observers.
Amendment 576 #
Proposal for a regulation Article 26 – paragraph 4 4. On the request of the Coordination Group, the Commission shall invite patients and clinical experts nominated by
Amendment 577 #
Proposal for a regulation Article 26 – paragraph 5 5. On the request of the Coordination Group, the stakeholder network shall support the Coordination Group in the identification of patient and clinical expertise
Amendment 578 #
Proposal for a regulation Article 26 – paragraph 5 5. On the request of the Coordination Group, the stakeholder network shall support the Coordination Group in the identification of further patient and clinical expertise for the work of its sub-groups.
Amendment 579 #
Proposal for a regulation Article 27 – paragraph 1 – introductory part 1.
Amendment 580 #
Proposal for a regulation Article 27 – paragraph 1 – point d a (new) (da) list of members of the Coordination Group, its sub-groups and other experts, together with their declaration of financial interests;
Amendment 581 #
Proposal for a regulation Article 27 – paragraph 1 – point d b (new) (db) final joint clinical assessment reports and summary reports in a lay- friendly format in all official languages of the European Union;
Amendment 582 #
Proposal for a regulation Article 27 – paragraph 1 – point d c (new) (dc) list of organisations included in the stakeholder network;
Amendment 583 #
Proposal for a regulation Article 27 – paragraph 2 2. The Commission shall ensure appropriate levels of access to the information contained in the IT platform for Member State bodies, members of the stakeholder network, and the general public. Information shall in principle be publicly accessible unless there are specific reasons to restrict access.
Amendment 584 #
Proposal for a regulation Article 27 – paragraph 2 2. The Commission shall ensure
Amendment 585 #
Proposal for a regulation Article 27 – paragraph 2 2. The Commission shall ensure
Amendment 586 #
Proposal for a regulation Article 27 – paragraph 2 a (new) 2a. A comprehensive summary report that is understandable to lay persons shall be provided for the publications referred to in paragraph 1. The content of that summary report shall be specified in consultation with patients and consumers’ organisations.
Amendment 587 #
Proposal for a regulation Article 28 – paragraph 1 Amendment 588 #
Proposal for a regulation Article 28 – paragraph 1 No later than two years after the end of the transitional period referred to in Article 33(1), the Commission shall
Amendment 589 #
Proposal for a regulation Article 28 – paragraph 1 No later than two years after the end of the transitional period referred to in Article 33(1), the Commission shall report on the implementation of the provisions on the scope and use of the joint clinical assessments and on the functioning of the support framework referred to in this Chapter.
Amendment 590 #
Proposal for a regulation Article 31 Amendment 591 #
Proposal for a regulation Article 32 – paragraph 2 2. When preparing those implementing and delegated acts, the Commission shall take into account the distinctive characteristics of the medicinal
Amendment 592 #
Proposal for a regulation Article 32 – paragraph 2 2. When preparing those implementing and delegated acts, the Commission shall take into account the distinctive characteristics of the medicinal product and medical device sectors and shall consider the work already undertaken in the EUnetHTA Joint Actions.
Amendment 593 #
Proposal for a regulation Article 32 – paragraph 2 2. When preparing those implementing and delegated acts, the Commission
Amendment 594 #
Proposal for a regulation Article 33 – paragraph 1 1. Member States may delay their participation in the system of joint clinical assessments and joint scientific consultations referred to in sections 1 and 2 of Chapter II until ... [insert date
Amendment 595 #
Proposal for a regulation Article 33 – paragraph 3 a (new) 3a. By way of derogation from Article 8 paragraph 1, Member States may choose to continue clinical assessments initiated before the date of application of this Regulation or the date referred to in paragraph 1 of this Article, if applicable.
Amendment 596 #
Proposal for a regulation Article 34 – paragraph 1 1. Member States may carry out a clinical assessment using means other than the rules provided for in Chapter III of this Regulation, on grounds related to the need to protect public health or other overriding reasons of public interest in the Member State concerned and provided the measure is justified, necessary and proportionate as regards achieving that aim.
Amendment 597 #
Proposal for a regulation Article 34 – paragraph 3 3. The Commission shall, within
Amendment 598 #
Proposal for a regulation Article 36 – paragraph 2 – subparagraph 1 (new) 5 years after the date of application, the Commission shall review the scope of the Regulation to include high-risk medical devices classified as class IIb and III pursuant to Article 51 of regulation (EU) 2017/745 for which the relevant expert panels have provided a scientific opinion in the framework of the clinical evaluation consultation procedure pursuant to Article 54 of that Regulation or in vitro diagnostic medical devices classified as class D pursuant to Article 47 of Regulation (EU) 2017/746 for which the relevant expert panels have provided their views in the framework of the procedure pursuant to Article 48(6) of that Regulation, where appropriate. The Commission shall take into account the implementation of Regulation (EU) 2017/745 and Regulation (EU) 2017/746.
source: 623.758
2018/06/18
ENVI
235 amendments...
Amendment 172 #
Proposal for a regulation Citation 1 Having regard to the Treaty on the Functioning of the European Union, and in particular Articles 114, 168(4) and 168(7) thereof,
Amendment 173 #
Proposal for a regulation Recital 1 (1) The development of health technologies is a key
Amendment 174 #
Proposal for a regulation Recital 1 (1) The development of health technologies is
Amendment 175 #
Proposal for a regulation Recital 1 (1) The development of health technologies is a key driver of economic growth and innovation in the Union. It forms part of an overall market for healthcare expenditure that accounts for 10% of EU gross domestic product, a percentage which, however, varies between Member States. Health technologies encompass medicinal products, medical devices and medical procedures, as well as measures for disease prevention, diagnosis or treatment.
Amendment 176 #
Proposal for a regulation Recital 1 (1) The development of health technologies is a key driver of economic growth and innovation for the benefit of all citizens in the Union. It forms part of an overall market for healthcare expenditure that accounts for 10% of EU gross domestic product. Health technologies encompass medicinal products, medical devices and medical procedures, as well as measures for disease prevention, diagnosis or treatment.
Amendment 177 #
Proposal for a regulation Recital 1 a (new) (1a) For this reason, it is essential that the development and design of health technology is done, from the very beginning, together with intended users to ensure the accessibility of the health technology for different kinds of users. The participatory development process should further consider the adaptability of health technology to the individual needs of each user with regards to the interfaces, applications and programmes design and functionality.
Amendment 178 #
Proposal for a regulation Recital 1 a (new) (1a) Marketing authorisations for medicinal products are granted by the European Medicines Agency based on the evaluation of efficacy, safety and quality, while it is normally the national HTA agencies that assess comparative effectiveness.
Amendment 179 #
Proposal for a regulation Recital 2 (2) Health Technology Assessment (HTA) is an evidence-based process that allows competent authorities to determine the relative effectiveness of new or existing technologies. HTA focuses specifically on the added value of a health technology in comparison with other new or existing health technologies
Amendment 180 #
Proposal for a regulation Recital 2 (2) Health Technology Assessment (HTA) is an evidence-based process that allows competent authorities to determine the relative effectiveness of new or existing technologies. HTA focuses specifically, as medical assessments generally do, on the added value of a health technology in comparison with other new or existing health technologies.
Amendment 181 #
Proposal for a regulation Recital 3 (3) HTA covers both clinical and non- clinical aspects of a health technology. The EU co-funded joint actions on HTA (EUnetHTA Joint Actions) have identified nine domains by reference to which health technologies are assessed. Of these nine domains, four are clinical and five are non- clinical. The four clinical domains of assessment concern the identification of a health problem and current technology, the examination of the technical characteristics of the technology under assessment, its relative safety, and its relative clinical
Amendment 182 #
Proposal for a regulation Recital 3 (3) HTA covers both clinical and non- clinical aspects of a health technology. The EU co-funded joint actions on HTA (EUnetHTA Joint Actions) have identified nine domains by reference to which health technologies are assessed. Of these nine domains, four are clinical and five are non- clinical. The four clinical domains of assessment concern the identification of a health problem and current technology, the examination of the technical characteristics of the technology under assessment, its relative safety, and its relative clinical effectiveness. The five non-clinical assessment domains concern cost and economic evaluation of a technology, its ethical, organisational, social, and legal aspects. The scientific aspects of the clinical domains are therefore more suited to joint assessment at EU-level on their scientific evidence base, while the assessment of non-clinical domains tends to be more closely related to national and regional contexts and approaches.
Amendment 183 #
Proposal for a regulation Recital 4 (4)
Amendment 184 #
Proposal for a regulation Recital 4 (4) The outcome of HTA is used to inform decisions concerning the allocation of budgetary resources in the field of health, for example, in relation to establishing the pricing or reimbursement levels of health technologies. HTA can therefore assist Member States in creating and maintaining sustainable healthcare systems and to stimulate innovation that delivers better outcomes for patients. In this regard, greater collaboration between Member States in the field of HTA should also help improve and harmonise standards of care as well as diagnosing and new born screening practices across the EU.
Amendment 185 #
Proposal for a regulation Recital 4 (4) The outcome of HTA is used to inform decisions concerning the allocation of budgetary resources in the field of health, for example, in relation to establishing the pricing or reimbursement levels of health technologies. HTA can therefore assist Member States in creating and maintaining sustainable healthcare systems and to stimulate innovation that delivers better outcomes for patients. The organisation of health care systems remains nevertheless a national competence.
Amendment 186 #
Proposal for a regulation Recital 4 (4) The outcome of HTA is used to inform decisions concerning the allocation of budgetary resources in the field of health, for example, in relation to establishing the pricing or reimbursement levels of health technologies or to identifying new and emerging technologies suitable for public funding. HTA can therefore assist Member States in creating and maintaining sustainable healthcare systems and to stimulate innovation that
Amendment 187 #
Proposal for a regulation Recital 4 a (new) (4a) Cooperation in the field of HTA can extend beyond pharmaceutical products and medical devices. It may also cover areas such as diagnostics used to supplement treatment, surgical procedures, prevention, screening and health promotion programmes, information and communications technology (ICT) tools, health-care organisation plans and integrated care processes. Different demands are involved in assessing different technologies, depending on their specific features, meaning that a cohesive approach which can cater for these different technologies is needed in the field of HTA. Moreover, in specific areas such as treatments for rare diseases, paediatric medicines, precision medicine and advanced therapies, the added value of cooperation at EU level is likely to be even greater.
Amendment 188 #
Proposal for a regulation Recital 4 a (new) (4a) Cooperation in the field of HTA can extend beyond pharmaceutical products and medical devices. Different demands are involved in assessing different technologies, depending on their specific features, meaning that a cohesive approach which can cater for these different technologies is needed in the field of HTA. Moreover, in specific areas such as treatments for rare diseases, paediatric medicines and advanced therapies, the added value of cooperation at EU level will be even greater. The specificities of orphan medicines should be taken into account within the implementation of this proposal in order to ensure rare disease patients are given the same opportunities to access treatments for their conditions.
Amendment 189 #
Proposal for a regulation Recital 5 (5) The carrying out of parallel assessments by multiple Member States and divergences between national laws, regulations and administrative provisions on the processes and methodologies of assessment can result in health technology developers being confronted with multiple and divergent requests for data. It can also lead to both duplications and variations in outcomes that increase the financial and administrative burdens that act as a barrier to the free movement of the health technologies concerned and the smooth functioning of the internal market. However, producing assessments that are not relevant for reimbursement decisions in certain Member States may delay the implementation of innovative technologies and thus access of patients to beneficial innovative treatments.
Amendment 190 #
Proposal for a regulation Recital 5 (5) The carrying out of parallel assessments by multiple Member States and divergences between national laws, regulations and administrative provisions on the processes and methodologies of assessment can result in health technology developers being confronted with multiple and divergent requests for data. It can also lead to both duplications and variations in outcomes that increase the financial and administrative burdens that act as a barrier to the free movement of the health technologies concerned and the smooth functioning of the internal market. In some justified cases where specificities of the national (and regional) healthcare system and priorities need to be taken into account a complementary assessment on certain aspects might be necessary.
Amendment 191 #
Proposal for a regulation Recital 5 (5) The carrying out of parallel assessments by multiple Member States and divergences between national laws, regulations and administrative provisions on the processes and methodologies of assessment can result in health technology developers being confronted with multiple and divergent requests for data. It can also lead to both duplications and variations in outcomes that increase the financial and administrative burdens that act as a barrier to the free movement of the health technologies concerned and the smooth functioning of the internal market. There are also economic benefits for Members States that can be gained through the reduction of duplications and variations in outcomes.
Amendment 192 #
Proposal for a regulation Recital 6 (6)
Amendment 193 #
Proposal for a regulation Recital 6 (6)
Amendment 194 #
Proposal for a regulation Recital 6 (6)
Amendment 195 #
Proposal for a regulation Recital 6 (6) While Member States have carried out some joint assessments within the framework of the EU co-funded joint actions, the production of output has been viewed by some as inefficient, relying on project-based cooperation in the absence of a sustainable model of cooperation. Use of the results of the joint actions, including their joint
Amendment 196 #
Proposal for a regulation Recital 8 (8) The European Parliament, in its resolution of 2 March 2017 on EU options for improving access to medicines,9 called on the Commission to propose legislation on a European system for health technology assessment as soon as possible and to harmonise transparent health technology assessment criteria in order to assess the
Amendment 197 #
Proposal for a regulation Recital 9 (9) In its 2015 Communication on upgrading the single market10, the Commission declared its intention to introduce an initiative on HTA to increase coordination in order to avoid multiple assessments of a product in different Member States and improve the functioning of the Single Market for health technologies
Amendment 198 #
Proposal for a regulation Recital 10 (10) In order to ensure a better functioning of the internal market and contribute to a high level of human health protection it is appropriate to approximate the rules on carrying out clinical assessments at national level and clinical assessments of certain health technologies at Union level, and which also support the continuation of voluntary cooperation between Member States on certain aspects of HTA. This approximation should guarantee the highest quality standards and be aligned to best available practice. It should not stimulate a convergence towards the lowest common denominator and force HTA bodies with more expertise and higher standards to accept lower requirements. It should rather lead to an improvement of the HTA capacity and quality at the national (and regional) level.
Amendment 199 #
Proposal for a regulation Recital 10 (10) In order to ensure a better functioning of the internal market and contribute to a high level of human health protection
Amendment 200 #
Proposal for a regulation Recital 11 (11) In accordance with Article 168(7) of the Treaty on the Functioning of the
Amendment 201 #
Proposal for a regulation Recital 11 (11) In accordance with Article 168(7) of the Treaty on the Functioning of the European Union (TFEU), the Member States remain responsible for the organisation and delivery of their healthcare. As such, it is appropriate to limit the scope of Union rules to those aspects of HTA that relate to the scientific aspects of the clinical assessment of a health technology, and in particular, to ensure that the assessment
Amendment 202 #
Proposal for a regulation Recital 11 (11) In accordance with Article 168(7) of the Treaty on the Functioning of the European Union (TFEU), the Member States remain responsible for the organisation and delivery of their healthcare. As such, it is appropriate to respect the principle of the freedom of the Member States to organise themselves and to limit the scope of Union rules to those aspects of HTA that relate to the clinical assessment of a health technology, and in particular, to ensure that the assessment conclusions are confined to findings relating to the comparative effectiveness of a health technology. The outcome of such assessments should not therefore under any circumstances affect the discretion of Member States in relation to subsequent decisions on pricing and reimbursement of health technologies, including the fixing of criteria for such pricing and reimbursement which may depend on both clinical and non-clinical considerations, and which remain solely a matter of national competence.
Amendment 203 #
Proposal for a regulation Recital 12 (12) In order to ensure a wide application of harmonised rules on clinical aspects of HTA and enable pooling of expertise and resources across HTA bodies, it is appropriate to require joint clinical assessments to be carried out for all medicinal products undergoing the central marketing authorisation procedure provided for under Regulation (EC) No 726/2004 of the European Parliament and of the Council,11 which incorporate a new active substance, and where those medicinal products are subsequently authorised for a new therapeutic indication.
Amendment 204 #
Proposal for a regulation Recital 12 (12) In order to ensure a wide application of harmonised rules on clinical aspects of HTA and enable pooling of expertise and resources across HTA bodies, it is appropriate to require joint clinical assessments to be carried out for all medicinal products undergoing the central marketing authorisation procedure provided for under Regulation (EC) No 726/2004 of the European Parliament and of the Council,11 which incorporate a new active substance, and where those medicinal products are subsequently authorised for a new therapeutic indication.
Amendment 205 #
Proposal for a regulation Recital 12 (12) In order to
Amendment 206 #
Proposal for a regulation Recital 12 (12) In order to
Amendment 207 #
Proposal for a regulation Recital 13 (13) In order to ensure that joint clinical assessments carried out on health technologies remain accurate
Amendment 208 #
Proposal for a regulation Recital 14 (14) A coordination group composed of representatives from Member States' health technology assessment authorities and bodies
Amendment 209 #
Proposal for a regulation Recital 14 a (new) (14a) In order for the clinical assessment to be used for the purposes of the national reimbursement decision, it should concern the population for which the drug would be reimbursed in a given Member State. The assessor and the co- assessor should have the responsibility for choosing a representative number of populations.
Amendment 210 #
Proposal for a regulation Recital 15 (15) In order to ensure a Member-State led approach to joint clinical assessments and scientific consultations, Member States should designate national HTA authorities and bodies which inform decision-making as members of the Coordination Group. The designated authorities and bodies should ensure an appropriately high level of representation in the Coordination Group and technical expertise in its sub- groups, taking into account the need to provide expertise on the HTA of medicinal products and medical devices. The organisational structure should respect the distinctive mandates of the sub-groups conducting the joint clinical assessments and the joint scientific consultations with separate member of the sub-groups performing these functions to avoid any conflict of interest.
Amendment 211 #
Proposal for a regulation Recital 15 (15) In order to ensure a Member-State led approach to joint clinical assessments and scientific consultations, Member States should
Amendment 212 #
Proposal for a regulation Recital 15 a (new) (15a) Health professionals, patients and the public who use and pay for health technologies need to know whether a new health technology is an improvement or not on existing health technologies, in terms of benefits and risks. Joint clinical assessments therefore aim to determine the added therapeutic value of new or existing health technologies in comparison with other new or existing health technologies. This is done by undertaking comparative assessment based on comparative trial data. In order to ensure that the therapeutic value of health technologies can be properly assessed, it is essential that comparative trials are done against the current best proven intervention (standard treatment) or against the current most common treatment where no standard treatment exists.
Amendment 213 #
Proposal for a regulation Recital 15 a (new) (15a) Joint scientific consultations shall concern the clinical study design, the determination of best comparators based on the best medical practice in the interest of patients. The process should be transparent. Joint scientific consultations results shall be made available to the general public.
Amendment 214 #
Proposal for a regulation Recital 15 b (new) (15b) In order to streamline the process and to make sure that joint clinical assessments are based on robust data, comparative trial data should be made available at the time of applications for marketing authorisations. Timely availability of data from comparative trials would go a long way towards facilitating HTA activities, saving time and resources, and benefitting patients and society thanks to a focus on real therapeutic advances.
Amendment 215 #
Proposal for a regulation Recital 15 b (new) (15b) The purpose of joint clinical assessments is to determine the added therapeutic value of new or existing technologies in comparison with other new or existing health technologies. Comparative assessment is undertaken by HTA bodies, who base their decision on comparative trial data with reference to the best standard therapies or the most common available treatment.
Amendment 216 #
Proposal for a regulation Recital 16 (16) In order that the harmonised procedures fulfil their internal market objective, Member States should be required to take full account of the results of joint clinical assessments and not repeat those assessments.
Amendment 217 #
Proposal for a regulation Recital 16 (16) In order that the harmonised procedures fulfil their internal market objective, Member States should be required to take full account of the results of joint clinical assessments and not repeat those assessments. Compliance with this obligation does not prevent Member States from carrying out complementary clinical assessments or non-clinical assessments on the same health technology, or from drawing conclusions on the added value of the technologies concerned as part of national appraisal processes which may consider clinical as well as non-clinical data and criteria. It also does not prevent Member States from forming their own recommendations or decisions on pricing or reimbursement.
Amendment 218 #
Proposal for a regulation Recital 16 (16) In order that the harmonised procedures fulfil their internal market objective, Member States should be
Amendment 219 #
Proposal for a regulation Recital 17 a (new) (17a) The joint scientific consultation, when addressing Orphan medicines, has to ensure that any new approach should not result in unnecessary delays for Orphan Medicinal Products assessment compared to the current situation and taken into account the pragmatic approach undergone through the EUnetHTA.
Amendment 220 #
Proposal for a regulation Recital 18 (18)
Amendment 221 #
Proposal for a regulation Recital 19 (19) In all cases the joint work carried out under this Regulation, in particular the joint clinical assessments, should produce high quality and timely results, and not delay or interfere with the CE marking of medical devices or market access of health technologies. This work should be separate and distinct from regulatory assessments of the safety, quality, efficacy or performance of health technologies carried out pursuant to other Union legislation and have no bearing on decisions taken in accordance with other Union legislation. In the framework of HTA, the joint report should not re-assess the elements on which the marketing authorisation is based, including the quality, safety, efficacy, bioequivalence, or biosimilarity of the medicinal product which have been already assessed during the marketing authorisation process. Similarly, in the case of orphan medicinal products, the joint report should not re-assess the criteria of the orphan designation. However, assessors and co-assessors should have full access to the data used by the authorities responsible for granting the marketing authorisation of a medicinal product, as well as the possibility of using or generating additional relevant data for the purpose of assessing a medicinal product in the context of a joint HTA.
Amendment 222 #
Proposal for a regulation Recital 19 (19) In all cases the joint work carried out under this Regulation, in particular the joint clinical assessments, should produce high quality and timely results, and not delay or interfere with the CE marking of medical devices or market access of health technologies. This work should be separate and distinct from regulatory assessments of the safety, quality, efficacy or performance of health technologies carried out pursuant to other Union legislation and have no bearing on decisions taken in accordance with other Union legislation. In the framework of HTA, the joint report should not-assess the elements on which the marketing authorisation is based, including the quality, safety, efficacy, bioequivalence, or biosimilarity of the medicinal product which have been already assessed during the marketing authorisation process. Similarly, in the case of orphan medicinal products, the joint report should not re-assess the criteria of the orphan designation. However, assessors and co-assessors should have full access to the data used by the authorities responsible for granting the marketing authorisation of a medicinal product, as well as the possibility of using or generating additional relevant data for the purpose of assessing a medicinal product in the context of a joint HTA.
Amendment 223 #
Proposal for a regulation Recital 19 (19) In all cases the joint work carried out under this Regulation, in particular the joint clinical assessments, should produce high quality and timely results, and not delay or interfere with the
Amendment 224 #
Proposal for a regulation Recital 19 a (new) (19a) The recently adopted Regulations (EU) No 2017/745 concerning medical devices and (EU) 2017/746 concerning in vitro diagnostic medical devices provide for the authorisation of such devices on the basis of the principles of transparency and safety and not on efficacy. However, the gradual increase in the supply of medical devices to address clinical conditions has heralded a paradigm shift towards a new model in which the market is highly fragmented, innovation is chiefly incremental and clinical evidence is lacking, which means that closer cooperation and more frequent exchanges of information between assessment bodies are needed. It is therefore necessary to move towards a centralised authorisation system that assesses devices on the basis of safety, efficacy and quality. This is one of the areas in which the Member States are calling for greater collaboration on a future European ETS. Twenty Member States, together with Norway, currently have health technology assessment systems for medical devices in place and 12 Member States, together with Norway, have established guidelines and are engaging in initial dialogues. EUnetHTA has been conducting high-quality evaluations of the relative efficacy of medical devices based on a methodology that can be taken as a benchmark in this proposal.
Amendment 225 #
Proposal for a regulation Recital 20 (20)
Amendment 226 #
Proposal for a regulation Recital 21 Amendment 227 #
Proposal for a regulation Recital 21 Amendment 228 #
Proposal for a regulation Recital 21 (21) Joint
Amendment 229 #
Proposal for a regulation Recital 21 a (new) (21a) According to the European Ombudsman, where the information in a document has implications for the health of individuals (such as information on the efficacy of a medicine), the public interest in disclosure will generally defeat any claim of commercial sensitivity. Public health should always trump commercial interests.
Amendment 230 #
Proposal for a regulation Recital 21 a (new) (21a) Joint scientific consultations should concern the clinical style design and the determination of best comparators based on the best medical practices in the interest of patients. The process should be transparent with the results of joint scientific consultations being made publicly available.
Amendment 231 #
Proposal for a regulation Recital 22 (22) In order to ensure the efficient use of available resources, it is appropriate to provide for "horizon scanning", to allow the early identification of emerging health technologies that are likely to have the most impact on patients, public health and healthcare systems. Such scanning should facilitate the prioritisation of technologies that are to be selected for joint clinical assessment. The available experience regarding the assessment of health technologies shows, however, that this type of horizon scanning is very difficult to implement and can be risky.
Amendment 232 #
Proposal for a regulation Recital 22 (22) In order to ensure the efficient use of available resources, it is appropriate to provide for “horizon scanning”
Amendment 233 #
Proposal for a regulation Recital 23 (23) The Union should continue to support voluntary cooperation on HTA between Member States in areas such as in the development and implementation of vaccination programmes, and capacity building of national HTA systems.
Amendment 234 #
Proposal for a regulation Recital 23 a (new) (23a) In order to ensure efficient decision-making and facilitate access to medicines it is important that appropriate frameworks and structures exist for cooperation across decision-makers at key stages of the medicines’ life cycle. This will help to avoid delays between marketing authorisation and subsequent decisions on access within the national healthcare systems. Relevant stages in the medicine life cycle are early dialogue on evidence plans as well as regulatory approval and HTA relative effectiveness assessments. These frameworks and structures shall facilitate exchange of information and knowledge whilst respecting the different remits of each decision maker.
Amendment 235 #
Proposal for a regulation Recital 25 (25) In order to ensure a uniform approach to the joint work provided for in this Regulation, implementing powers should be conferred on the Commission to establish a common procedural and methodological framework for clinical assessments, procedures for joint clinical assessments and procedures for joint scientific consultations. Where appropriate, distinct rules should be developed for
Amendment 236 #
Proposal for a regulation Recital 25 (25) In order to ensure a uniform approach to the joint work provided for in this Regulation,
Amendment 237 #
Proposal for a regulation Recital 25 a (new) (25a) The Commission, together with the Member States, should adapt the framework of joint clinical assessment to vaccines to take into account the vaccines preventive nature that brings benefits to individuals and populations over a long time horizon, and should involve the appropriate national bodies in the joint clinical assessment of vaccines. The adaption of the framework should be completed by the end of the implementation period to ensure that it is ready to be used during the transition period.
Amendment 238 #
Proposal for a regulation Recital 25 a (new) (25a) The Commission, together with Member States, should adapt the framework of joint clinical assessment to vaccines to take into account their preventive nature that brings benefits to individuals and populations over a long time horizon. They should involve the appropriate national bodies in the joint clinical assessment of vaccines.
Amendment 239 #
Proposal for a regulation Recital 27 a (new) (27a) The availability of sufficient capacity at the national (and regional) level is of paramount importance in order to ensure contribution from all Member States to the joint work. The Union will therefore provide funding for training and capacity building to stimulate exchange of experience between national authorities and experts and ensure alignment of quality standards together with a balanced distribution of the workload.
Amendment 240 #
Proposal for a regulation Recital 28 a (new) (28a) The Coordination Group, composed of national and/or regional authorities and bodies responsible for health technology assessment, with proven capacity, independence and impartiality, shall draw up the methodology for ensuring high quality of work as a whole. The Commission shall provide administrative support for the joint work of the Coordination Group, which, after consultation with the stakeholders, shall submit the final report on this work.
Amendment 241 #
Proposal for a regulation Recital 29 (29) In order to ensure the smooth establishment and operation of Union-level joint assessments, as well as to safeguard their quality, it is appropriate to provide for a transitional period allowing a progressive expansion of the number of joint assessments carried out annually. The number of assessments to be carried out should be determined with due regard for the resources available and the number of Member States opting freely to participat
Amendment 242 #
Proposal for a regulation Recital 30 (30) During the transitional period, participation in joint clinical assessments and joint scientific consultations should not be mandatory for Member States. This should not affect the obligation of Member States to apply harmonised rules to clinical assessments carried out at a national level. During the transitional period, Member States not participating in the joint work may at any time decide to participate. In order to ensure a stable and smooth organisation of the joint work and the
Amendment 243 #
Proposal for a regulation Recital 30 (30) During the transitional period, participation in joint clinical assessments and joint scientific consultations should not under any circumstances be mandatory for Member States. This should not affect the obligation of Member States to apply harmonised rules to clinical assessments carried out at a national level. During the transitional period, Member States not participating in the joint work may at any time decide to participate. In order to ensure a stable and smooth organisation of the joint work and the functioning of the internal market, Members States which are already participating should not be allowed to withdraw from the framework for joint work.
Amendment 244 #
Proposal for a regulation Recital 31 (31) In order to ensure that the support framework continues to be as efficient and cost-effective as possible, the Commission should report on the implementation of the provisions on the scope of the joint clinical assessments and
Amendment 245 #
Proposal for a regulation Recital 31 (31) In order to ensure that the support framework continues to be as efficient and cost-effective as possible, the Commission should report on the implementation of the provisions on the scope of the joint clinical assessments
Amendment 246 #
Proposal for a regulation Recital 31 (31) In order to ensure that the support framework continues to be as efficient and cost-effective as possible, the Commission should report on the implementation of the provisions on the scope of the joint clinical assessments and on the functioning of the support framework no later than two years after the end of the transitional period.
Amendment 247 #
Proposal for a regulation Recital 31 (31) In order to ensure that the support framework continues to be as efficient and cost-effective as possible, the Commission should report on the implementation of the provisions on the scope of the joint clinical assessments and on the functioning of the support framework no later than two years after the end of the transitional period.
Amendment 248 #
Proposal for a regulation Recital 31 (31) In order to ensure that the support framework continues to be as efficient and cost-effective as possible, the Commission should report on the implementation of the provisions on the scope of the joint clinical assessments and on the functioning of the support framework no later than two years after the end of the transitional period.
Amendment 249 #
Proposal for a regulation Recital 31 (31) In order to ensure that the support framework continues to be as efficient and cost-effective as possible, the Commission should report on the implementation of the
Amendment 250 #
Proposal for a regulation Recital 34 (34) Since the objectives of this Regulation
Amendment 251 #
Proposal for a regulation Article 1 – paragraph 1 – introductory part 1. Taking into account the results of the work already undertaken in the EUnetHTA Join Actions, this Regulation establishes:
Amendment 252 #
Proposal for a regulation Article 1 – paragraph 1 – introductory part 1.
Amendment 253 #
Proposal for a regulation Article 1 – paragraph 2 2. This Regulation shall not affect the
Amendment 254 #
Proposal for a regulation Article 2 – paragraph 1 – point b a (new) (ba) assessments of a ‘medical device’ may also mean the assessment of a method composed of more than one medical device or a method composed of a medical device and a defined care chain of other treatments.
Amendment 255 #
Proposal for a regulation Article 2 – paragraph 1 – point e (e) ‘clinical assessment
Amendment 256 #
Proposal for a regulation Article 2 – paragraph 1 – point e (e) ‘joint clinical assessment’ means a compilation and
Amendment 257 #
Proposal for a regulation Article 2 – paragraph 1 – point e (e) ‘clinical assessment’ means a compilation and evaluation of the available scientific evidence on a health technology in comparison with one or more other health technologies based on the following clinical domains of health technology assessment: the description of the health problem addressed by the health technology and the current use of other health technologies addressing that health problem, the description and technical characterisation of the health technology
Amendment 258 #
Proposal for a regulation Article 2 – paragraph 1 – point e (e) ‘clinical assessment’ means a compilation and evaluation of the available scientific evidence on a health technology in comparison with one or more other health technologies based on the following clinical domains of health technology assessment: the description of the health
Amendment 259 #
Proposal for a regulation Article 2 – paragraph 1 – point g a (new) (ga) ‘appraisal’ means drawing conclusions on the added value of the technologies concerned as part of national appraisal processes which may consider clinical as well as non-clinical data and criteria.
Amendment 260 #
Proposal for a regulation Article 2 – paragraph 1 – point g a (new) (ga) ‘patient-relevant outcomes’ or ‘patient relevant endpoints’ means data that captures or predicts mortality, morbidity, health related quality of life (including pain, recovery rates and time, length of stay in hospital), adverse events (including re-admissions, complications, blood loss, infections).
Amendment 261 #
Proposal for a regulation Article 2 – paragraph 1 – point g b (new) (gb) ‘patient-relevant health outcomes’ means data that captures or predicts mortality, morbidity, health-related quality of life and adverse events.
Amendment 262 #
Proposal for a regulation Article 3 – paragraph 1 1. The Member State Coordination
Amendment 263 #
Proposal for a regulation Article 3 – paragraph 2 2. Member States shall designate their national authorities and bodies responsible for health technology assessment as members of the Coordination Group and its sub-groups and inform the Commission thereof and of any subsequent changes. Member States may designate more than one authority or body responsible for health technology assessment as members of the Coordination Group and one or more of its sub-groups.
Amendment 264 #
Proposal for a regulation Article 3 – paragraph 2 2. Member States shall designate their national authorities and bodies responsible for health technology assessment which inform decision making as members of the Coordination Group and its sub-groups and inform the Commission thereof and of any subsequent changes. Member States may designate more than one authority or body responsible for health technology assessment which inform decision-making as members of the Coordination Group and one or more of its sub-groups..
Amendment 265 #
Proposal for a regulation Article 3 – paragraph 2 2. Member States shall designate their national authorities and bodies responsible for health technology assessment as members of the Coordination Group and its sub-groups and inform the Commission thereof and of any subsequent changes. Member States
Amendment 266 #
Proposal for a regulation Article 3 – paragraph 2 a (new) 2a. The Commission shall nominate two representatives of patient organisations as full members of the Coordination Group, to be selected from a list of eligible candidates drawn up by the European Commission following a public call for expressions of interest. The patient representatives will hold voting rights.
Amendment 267 #
Proposal for a regulation Article 3 – paragraph 3 3. The Coordination Group shall a
Amendment 268 #
Proposal for a regulation Article 3 – paragraph 3 3. The Coordination Group shall act by consensus, or, where n
Amendment 269 #
Proposal for a regulation Article 3 – paragraph 3 3. The Coordination Group shall act by consensus, or, where necessary, vote by
Amendment 270 #
Proposal for a regulation Article 3 – paragraph 3 3. The Coordination Group shall act by consensus, or, where n
Amendment 271 #
Proposal for a regulation Article 3 – paragraph 3 3. The Coordination Group shall act by consensus, or, where necessary, vote by
Amendment 272 #
Proposal for a regulation Article 3 – paragraph 3 3. The Coordination Group shall act by consensus, or, where necessary, vote by
Amendment 273 #
Proposal for a regulation Article 3 – paragraph 3 3. The Coordination Group shall act by consensus, or, where necessary, vote by
Amendment 274 #
Proposal for a regulation Article 3 – paragraph 3 3. The Coordination Group shall act by consensus
Amendment 275 #
Proposal for a regulation Article 3 – paragraph 3 3. The Coordination Group shall act by consensus, or, where necessary, vote by simple majority. There shall be one vote per Member State. Votes shall be recorded. Dissensions and minority opinions should be motivated and also included in the assessment.
Amendment 276 #
Proposal for a regulation Article 3 – paragraph 4 4. Meetings of the Coordination Group shall be
Amendment 277 #
Proposal for a regulation Article 3 – paragraph 4 4. Meetings of the Coordination Group shall be
Amendment 278 #
Proposal for a regulation Article 3 – paragraph 4 4. Meetings of the Coordination Group shall be co-chaired by the Commission, without the right to vote, and a co-chair elected from the members of the group for a set term to
Amendment 279 #
Proposal for a regulation Article 3 – paragraph 5 5. Members o
Amendment 280 #
Proposal for a regulation Article 3 – paragraph 5 5. Members of the Coordination Group shall appoint their representatives in
Amendment 281 #
Proposal for a regulation Article 3 – paragraph 5 a (new) 5a. Members of the Stakeholder Network shall appoint their representatives to be members of the Coordination Group and the sub-groups, on an ad-hoc or permanent basis, and inform the Commission of their appointment any subsequent changes. The appointments shall take into account the expertise necessary for the objectives of the sub-group.
Amendment 282 #
Proposal for a regulation Article 3 – paragraph 6 6. Members of the Coordination Group, and their appointed representatives shall respect the principles of
Amendment 283 #
Proposal for a regulation Article 3 – paragraph 6 6. Members of the Coordination Group, and their appointed representatives shall respect the principles of independence, impartiality, transparency and confidentiality.
Amendment 284 #
Proposal for a regulation Article 3 – paragraph 6 6. Members of the Coordination Group, and their appointed representatives shall respect the principles of independence, impartiality, and confidentiality. Transparency and publicity of the process is essential. In this connection, all clinical data being evaluated should have the highest level of transparency and publicity in order to gain confidence in the system. In case there is confidential data for commercial reasons, the confidentiality needs to be clearly defined and justified and the confidential data well delimitated.
Amendment 285 #
Proposal for a regulation Article 3 – paragraph 6 6. Members of the Coordination Group, and their appointed representatives shall respect the principles of independence, impartiality, and confidentiality. They shall fill in a declaration of interest which must be made public via the IT platform referred to in Article 27.
Amendment 286 #
Proposal for a regulation Article 3 – paragraph 6 6. Members of the Coordination Group, and their appointed representatives shall respect the principles of transparency, independence, impartiality, and confidentiality.
Amendment 287 #
Proposal for a regulation Article 3 – paragraph 7 7. The Commission shall publish a list of the designated members of the Coordination Group and its sub-groups
Amendment 288 #
Proposal for a regulation Article 3 – paragraph 8 – point a a (new) (aa) adopt rules on conflicts of interest to ensure the integrity and independence of the coordination groups, joint clinical assessments and joint scientific consultations;
Amendment 289 #
Proposal for a regulation Article 3 – paragraph 8 – point c (c) ensure regular cooperation with all relevant Union level bodies to facilitate additional evidence generation necessary for its work;
Amendment 290 #
Proposal for a regulation Article 3 – paragraph 8 – point d (d) ensure appropriate
Amendment 291 #
Proposal for a regulation Article 3 – paragraph 8 – point d (d) ensure appropriate involvement of stakeholders
Amendment 292 #
Proposal for a regulation Article 3 – paragraph 8 – point d (d) ensure appropriate involvement of stakeholders in its work, including of intended users of health technology;
Amendment 293 #
Proposal for a regulation Article 3 – paragraph 8 – point d (d) ensure appropriate involvement of all relevant stakeholders in its work;
Amendment 294 #
Proposal for a regulation Article 3 – paragraph 8 – point d (d) ensure appropriate and regular involvement of stakeholders in its work;
Amendment 295 #
Proposal for a regulation Article 3 – paragraph 8 – point e – point i Amendment 296 #
Proposal for a regulation Article 3 – paragraph 8 – point e – point iii (iii) identification of emerging health technologies and analysis of the accessibility of health technologies to ensure they do not unintentionally increase inequalities in access to health;
Amendment 297 #
Proposal for a regulation Article 3 – paragraph 9 9. The Coordination Group may meet in different configurations for the
Amendment 298 #
Proposal for a regulation Article 3 – paragraph 10 10. The Coordination Group may establish separate sub-groups deemed necessary to conduct their mandate for the following categories of health technology: medicinal products, medical devices, and other health technologies.
Amendment 299 #
Proposal for a regulation Article 3 – paragraph 10 10. The Coordination Group may establish separate sub-groups for the following categories of health technology: medicinal products, medical devices, in vitro diagnostic medical devices and other health technologies.
Amendment 300 #
Proposal for a regulation Article 4 – paragraph 1 1. The
Amendment 301 #
Proposal for a regulation Article 4 – paragraph 3 – introductory part 3. In the preparation of the annual work programme, the
Amendment 302 #
Proposal for a regulation Article 4 – paragraph 3 – point c (c)
Amendment 303 #
Proposal for a regulation Article 4 – paragraph 3 – point c (c)
Amendment 304 #
Proposal for a regulation Article 4 – paragraph 3 – point c (c)
Amendment 305 #
Proposal for a regulation Article 4 – paragraph 3 – point c (c) consult the Commission on the draft annual work programme
Amendment 306 #
Proposal for a regulation Article 4 – paragraph 3 – point c a (new) (ca) consult with the representatives of patients and intended end-users of health technology and take into account their needs and opinions.
Amendment 307 #
Proposal for a regulation Article 4 – paragraph 3 – point c a (new) (ca) consult with stakeholders who are independent from commercial interests.
Amendment 308 #
Proposal for a regulation Article 4 – paragraph – point c a (new) (ca) consult civil society organisations, patient associations, social partners, consumer organisations, healthcare professionals and non-governmental organisations in the field of health technology assessment.
Amendment 309 #
Proposal for a regulation Article 5 – paragraph 1 – point a (a) medicinal products subject to the authorisation procedure provided for in Regulation (EC) No 726/2004
Amendment 310 #
Proposal for a regulation Article 5 – paragraph 1 – point a (a) medicinal products subject to the authorisation procedure provided for in Regulation (EC) No 726/2004, including where an amendment has been made to the Commission Decision to grant a marketing authorisation based on a change in the therapeutic indication or indications for which the original authorisation was granted, with the exception of medicinal products authorised under Article 10 and medicinal products composed of patent active substances authorised under Articles 10a and 10
Amendment 311 #
Proposal for a regulation Article 5 – paragraph 1 – point a a (new) (aa) applications for new therapeutic indications for medicinal products authorised in accordance with Regulation (EC) No 726/2004.
Amendment 312 #
Proposal for a regulation Article 5 – paragraph 1 – point b Amendment 313 #
Proposal for a regulation Article 5 – paragraph 1 – point b Amendment 314 #
Proposal for a regulation Article 5 – paragraph 1 – point b Amendment 315 #
Proposal for a regulation Article 5 – paragraph 1 – point b – subparagraph 1 a (new) The Commission shall, by means of Delegated Acts, include in Article 5 paragraph 1 of this Regulation a specific product category of medical devices if at least five Member States are systematically performing health technology assessments on the same specific product category of medical devices.
Amendment 316 #
Proposal for a regulation Article 5 – paragraph 1 – point b a (new) (ba) other medical devices considered to be major innovations or with potential significant impacts on national health care systems;
Amendment 317 #
Proposal for a regulation Article 5 – paragraph 1 – point c Amendment 318 #
Proposal for a regulation Article 5 – paragraph 1 – point c Amendment 319 #
Proposal for a regulation Article 5 – paragraph 1 – point c Amendment 320 #
Proposal for a regulation Article 5 – paragraph 1 – point c – subparagraph 1 a (new) The Commission shall, by means of Delegated acts, include in Article 5 paragraph 1 of this Regulation a specific product category of in vitro diagnostic medical devices if at least five Member States are systematically performing health technology assessments on the same specific product category of in vitro diagnostic medical devices.
Amendment 321 #
Proposal for a regulation Article 5 – paragraph 2 Amendment 322 #
Proposal for a regulation Article 5 – paragraph 2 Amendment 323 #
Proposal for a regulation Article 5 – paragraph 2 – introductory part 2. The Coordination Group shall select the medical devices referred to in paragraph 1 points (b), (ba) and (c) for joint clinical assessment based on the following criteria:
Amendment 324 #
Proposal for a regulation Article 5 – paragraph 2 – point e a (new) (ea) the application from the health technology developer;
Amendment 325 #
Proposal for a regulation Article 5 a (new) Article 5a Standards and comparative trials 1. In order to ensure evidence-based methodological standards in joint clinical assessments, the added therapeutic value should be demonstrated on patient- relevant endpoints such as mortality, morbidity or quality of life. The manufacturers shall provide all data from all sponsored studies in the indication under assessment. Joint assessments shall be discontinued or disregarded by Member States in case of non- compliance. 2. Marketing authorisation applicants shall conduct at least one randomised clinical trial comparing new medication with an active comparator among the best current intervention at the time of trial design, i.e. standard treatment, or the most common intervention when no standard treatment exists. The sponsor is expected to comply with established product development guidelines and to take up-to-date medical knowledge into account so as to establish the best comparative alternative. Full results of comparative trials, including raw and individual patient data (clinical study reports) shall be made available upon application for a marketing authorisation and included in HTA applications. Upon conclusion of the joint clinical assessment, all information and data shall be made publicly available pursuant to Regulation 1049/2001/EC. If the sponsor obtained but failed to follow scientific advice on data and evidence requirements, the sponsor shall justify this deviation.
Amendment 326 #
Proposal for a regulation Article 5 a (new) Article 5a Methodological standards: standard of care, comparator and endpoints 1. Joint clinical assessments shall be based on the highest standards of evidence-based medicine. Added therapeutic value shall be demonstrated on patient-relevant endpoints: mortality, morbidity, quality of life, according to the situation. 2. Health technology developers shall provide all data from all sponsored studies in relation to the health technology under assessment. In the case of non- compliance with this requirement, the joint assessment may be postponed or terminated. The names of health technology developers who fail to provide all data shall be published on the IT platform established in Article 27.
Amendment 327 #
Proposal for a regulation Article 5 b (new) Article 5b Conduct of comparative trials against standard treatment 1. Health technology developers shall conduct at least one randomised clinical trial comparing the health technology under assessment with an active comparator considered among the best current proven interventions at the time of the design of the trial (‘standard treatment’), or the most common intervention where no standard treatment exists. The health technology developer shall comply with established guidelines on development of products and shall take into account the most up to date medical knowledge when determining the best comparator. 2. Full results of the comparative trials, including raw and individual patient data (clinical study reports) should be made available at the time of the applications for a marketing authorisation and included in HTA applications. As soon as the joint clinical assessment is finalised, all information and data should be made publicly available as provided for by Regulation 1049/2001 as well as being published on the IT platform established in Article 27. 3. If the health technology developer obtained scientific advice on data and evidence requirements via the joint scientific consultation, and did not follow the advice, they shall justify the deviation from the advice given.
Amendment 328 #
Proposal for a regulation Article 6 – paragraph 1 – subparagraph 1 The Coordination Group shall initiate joint clinical assessments of health technologies on the basis of its annual work programme
Amendment 329 #
Proposal for a regulation Article 6 – paragraph 1 – subparagraph 1 The Coordination Group shall initiate joint clinical assessments of health technologies on the basis of its annual work programme by designating a sub-group to oversee the preparation of the joint clinical assessment report on behalf of the Coordination Group. Member States may propose additional comparator, which from their point of view represents the relevant evidence-based standard of care in their Member State. In case this proposal has not been taken into account, the relevant Member State may use the mechanism referred to in Article 8 – paragraph 1 a (new).
Amendment 330 #
Proposal for a regulation Article 6 – paragraph 1 – subparagraph 1 The Coordination Group shall initiate joint clinical assessments of health technologies on the basis of its annual work programme by designating a sub-group to oversee the preparation of the joint clinical assessment report on behalf of the Coordination Group. For medicinal products referred to in Article 5(1)(a), the joint clinical assessment report shall be adopted by the Coordination Group within 90 days in order to ensure compliance with timelines for pricing and reimbursement set out in Council Directive 89/105/EEC.
Amendment 331 #
Proposal for a regulation Article 6 – paragraph 1 – subparagraph 2 The joint clinical assessment report shall be accompanied by a summary report and the
Amendment 332 #
Proposal for a regulation Article 6 – paragraph 1 – subparagraph 2 The joint clinical assessment report shall be accompanied by a summary report and they shall be prepared in accordance with the requirements in this Article
Amendment 333 #
Proposal for a regulation Article 6 – paragraph 1 – subparagraph 2 The joint clinical assessment report shall be accompanied by a summary report and they shall be prepared in accordance with the requirements in this Article and the requirements established pursuant to
Amendment 334 #
Proposal for a regulation Article 6 – paragraph 1 – subparagraph 2 The joint clinical assessment report shall be accompanied by a summary report and they shall be prepared in accordance with the requirements in this Article and the requirements established pursuant to Articles 11, 22, and 23 and the procedures and work resulting from EUnetHTA joint actions for the joint clinical assessment of pharmaceuticals.
Amendment 335 #
Proposal for a regulation Article 6 – paragraph 1 – subparagraph 2 The joint clinical assessment report shall be accompanied by a summary report and they shall be prepared in accordance with the requirements in this Article and the requirements established pursuant to Articles 11, 22, and 23.
Amendment 336 #
Proposal for a regulation Article 6 – paragraph 2 2. The designated sub-group shall request
Amendment 337 #
Proposal for a regulation Article 6 – paragraph 2 2. The designated sub-group shall request relevant health technology developers to submit comprehensive documentation containing the information, data and evidence necessary for the joint clinical assessment. The relationship between evaluators and health technology developers, however, must be independent and impartial. Developers of health technologies can be consulted but not actively participate in the evaluation process.
Amendment 338 #
Proposal for a regulation Article 6 – paragraph 2 2. The designated sub-group shall request relevant health technology developers to submit comprehensive documentation containing the information, all available data and evidence
Amendment 339 #
Proposal for a regulation Article 6 – paragraph 2 2. The designated sub-group shall request relevant health technology developers to submit comprehensive documentation containing
Amendment 340 #
Proposal for a regulation Article 6 – paragraph 2 2. The designated sub-group shall request relevant health technology developers to submit documentation containing the information, data and evidence necessary for the joint clinical assessment. The submitted documentation must include all available evidence and data for the joint clinical assessment.
Amendment 341 #
Proposal for a regulation Article 6 – paragraph 2 2. The designated sub-group shall request relevant health technology
Amendment 342 #
Proposal for a regulation Article 6 – paragraph 2 2. The designated sub-group shall request relevant health technology developers to submit documentation
Amendment 343 #
Proposal for a regulation Article 6 – paragraph 2 2. The
Amendment 344 #
Proposal for a regulation Article 6 – paragraph 2 – subparagraph 1 (new) The information should note how intended users of the health technology have been involved in the planning, development and design of the technology.
Amendment 345 #
Proposal for a regulation Article 6 – paragraph 2 – subparagraph 1 (new) The content of the requested documentation should be clearly specified to avoid unnecessary duplication with national or regional requirements.
Amendment 346 #
Proposal for a regulation Article 6 – paragraph 2 – subparagraph 2 (new) At an appropriate time point after the application of the Regulation an impact assessment should be conducted by the Commission to assess difference in requirements demanded from technology developers.
Amendment 347 #
Proposal for a regulation Article 6 – paragraph 2 a (new) 2a. Where the health technology under assessment is an orphan medicinal product, the Coordination Group shall consider whether a joint clinical assessment is necessary based on the availability of any additional data and evidence, further than the ones already submitted to the European Medicines Agency for the purposes of establishing a significant benefit assessment pursuant to Regulation (EC) No 141/2000. Where the Coordination Group subsequently concludes that there is no substantive reason or additional evidence to support further clinical analysis beyond the significant benefit assessment already carried by the European Medicines Agency, the conclusions of the joint clinical assessment report shall be in line with the opinion of the Committee for Orphan Medicinal Products.
Amendment 348 #
Proposal for a regulation Article 6 – paragraph 2 a (new) 2a. The designated sub-group shall also request additional data from relevant sources, such as patient registries, databases or European Reference Networks, where this is deemed necessary to complement the information provided by the developer and to perform a more accurate clinical assessment of the health technology.
Amendment 349 #
Proposal for a regulation Article 6 – paragraph 2 a (new) 2a. The designated sub-group shall also request additional data from relevant sources, such as patient registries, databases or European Reference Networks, where this is deemed necessary to complete the information provided by the developer and to perform a more accurate clinical assessment of the health technology.
Amendment 350 #
Proposal for a regulation Article 6 – paragraph 2 b (new) 2b. Relevant health technology developers shall include developers of technologies that are already authorised and which serve as comparators for the new one.
Amendment 351 #
Proposal for a regulation Article 6 – paragraph 2 c (new) 2c. When relevant developers are requested to submit documentation necessary for the joint clinical assessment, they have the obligation to do so. Failure to do so will result in an explicit mention in the report.
Amendment 352 #
Proposal for a regulation Article 6 – paragraph 3 3. The
Amendment 353 #
Proposal for a regulation Article 6 – paragraph 4 a (new) Amendment 354 #
Proposal for a regulation Article 6 – paragraph 5 – introductory part 5. The conclusions of the joint clinical assessment report shall
Amendment 355 #
Proposal for a regulation Article 6 – paragraph 5 – introductory part 5. The
Amendment 356 #
Proposal for a regulation Article 6 – paragraph 5 – point a (a) an analysis of the relative effects of the health technology being assessed on the patient-relevant health outcomes chosen for the assessment compared to one or more comparator treatments to be determined by the Coordination Group;
Amendment 357 #
Proposal for a regulation Article 6 – paragraph 5 – point a (a) an analysis of the relative effects of the health technology being assessed on the patient-relevant health outcomes chosen for the assessment, including mortality, morbidity and quality of life;
Amendment 358 #
Proposal for a regulation Article 6 – paragraph 5 – point a (a) an analysis of the
Amendment 359 #
Proposal for a regulation Article 6 – paragraph 5 – point a (a) a
Amendment 360 #
Proposal for a regulation Article 6 – paragraph 5 – point a (a) an analysis of the re
Amendment 361 #
Proposal for a regulation Article 6 – paragraph 5 – point a – subpoint 1 (new) The analysis shall include consideration for the accessibility of the technology concerned and how to ensure it does not increase inequalities in access to health.
Amendment 362 #
Proposal for a regulation Article 6 – paragraph 5 – point b (b) the degree of certainty on the relative effects based on the available evidence. The assessment shall be based on the clinical endpoints established according to international standards of evidence-based medicine, in particular with regard to improving the state of health, shortening the duration of the disease, prolonging survival, reducing side effects or improving the quality of life. Reference should also be made to subgroup-specific differences.
Amendment 363 #
Proposal for a regulation Article 6 – paragraph 5 – point b (b) the degree of certainty on the relative effects based on the available evidence. The conclusions do not include an appraisal of the clinical efficacy of the health technology assessed or any recommendations for such an appraisal.
Amendment 364 #
Proposal for a regulation Article 6 – paragraph 5 – point b (b) the degree of certainty on the relative effects based on
Amendment 365 #
Proposal for a regulation Article 6 – paragraph 5 – subparagraph 1 (new) The assessor and the co-assessor shall make sure that the choice of relevant patient groups is representative for the Member States participating to enable them to take appropriate decisions on funding these technologies from national health budgets.
Amendment 366 #
Proposal for a regulation Article 6 – paragraph 6 6. Where, at any stage in the preparation of the draft joint clinical assessment report, the assessor considers that additional evidence from the submitting health technology developer is necessary in order to complete the report, it may request the
Amendment 367 #
Proposal for a regulation Article 6 – paragraph 7 7. The members of the designated sub-group shall provide their comments during the preparation of the draft joint clinical assessment report and the summary report. A minimum time frame of 30 work- days is provided for members of the sub-group to comment on the draft report, and procedural aspects will be decided as provided for in Article 11. The Commission may also provide comments.
Amendment 368 #
Proposal for a regulation Article 6 – paragraph 7 7. The members of the designated sub-group or the Coordination Group shall provide their comments during the preparation of the draft joint clinical assessment report and the summary report. The Commission may also provide comments.
Amendment 369 #
Proposal for a regulation Article 6 – paragraph 7 7. The members of the designated sub-group shall provide their comments during the preparation of the draft joint clinical assessment report and the summary report.
Amendment 370 #
Proposal for a regulation Article 6 – paragraph 7 7. The members of the
Amendment 371 #
Proposal for a regulation Article 6 – paragraph 7 7. The members of the designated sub-group, in a minimum time frame of 30 work days, shall provide their comments during the preparation of the draft joint clinical assessment report and the summary report.
Amendment 372 #
Proposal for a regulation Article 6 – paragraph 8 Amendment 373 #
Proposal for a regulation Article 6 – paragraph 8 Amendment 374 #
Proposal for a regulation Article 6 – paragraph 9 9. The designated sub-group shall ensure that
Amendment 375 #
Proposal for a regulation Article 6 – paragraph 8 8. The assessor shall provide the draft joint clinical assessment report and the summary report to the submitting health technology developer for fact-checking purposes and set a time-frame in which the developer may submit comments.
Amendment 376 #
Proposal for a regulation Article 6 – paragraph 9 9.
Amendment 377 #
Proposal for a regulation Article 6 – paragraph 9 9. The designated sub-group shall ensure that stakeholders, including
Amendment 378 #
Proposal for a regulation Article 6 – paragraph 9 9. The designated sub-group shall ensure that stakeholders, including patients’ associations and clinical experts, civil society organizations, social partners, consumer organizations, healthcare professionals and NGOs are given an
Amendment 379 #
Proposal for a regulation Article 6 – paragraph 9 9. The designated sub-group shall ensure that stakeholders, including patients and clinical experts, are given an opportunity to provide comments during the preparation of the draft joint clinical assessment report and the summary report and set a time-frame in which they may submit comments. To ensure appropriate consultation on the draft summary report, different versions in different EU languages should be available.
Amendment 380 #
Proposal for a regulation Article 6 – paragraph 9 9. The designated sub-group shall ensure that stakeholders, including patients, consumer organisations and clinical experts, are given an opportunity to provide comments during the preparation of the draft joint clinical assessment report and the summary report and set a time- frame in which they may submit comments.
Amendment 381 #
Proposal for a regulation Article 6 – paragraph 9 9. The
Amendment 382 #
Proposal for a regulation Article 6 – paragraph 9 a (new) 9a. A robust governance structure to ensure independence and quality of experts will be worked out by the Commission, through delegated act.
Amendment 383 #
Proposal for a regulation Article 6 – paragraph 10 10. Following receipt and consideration of a
Amendment 384 #
Proposal for a regulation Article 6 – paragraph 10 10. Following receipt and consideration of any comments provided in accordance
Amendment 385 #
Proposal for a regulation Article 6 – paragraph 10 10. Following receipt and consideration of any comments provided in accordance with paragraphs 7, 8, and 9, the assessor, with the assistance of the co-assessor, shall finalise the draft joint clinical assessment report and summary report, and submit those reports to the designated sub-group and to the Commission for comments. All comments shall be published on the IT platform referred to in Article 27.
Amendment 386 #
Proposal for a regulation Article 6 – paragraph 10 10. Following receipt and consideration of any comments provided in accordance with paragraphs 7, 8, and 9, the assessor, with the assistance of the co-assessor, shall finalise the draft joint clinical assessment report and summary report, and submit those reports to the designated sub-group and to the Commission for comments on procedural aspects.
Amendment 387 #
Proposal for a regulation Article 6 – paragraph 11 11. The assessor, with the assistance of the co-assessor, shall take into account the comments of the designated sub-group
Amendment 388 #
Proposal for a regulation Article 6 – paragraph 11 11. The assessor, with the assistance of the co-assessor, shall take into account the comments of the
Amendment 389 #
Proposal for a regulation Article 6 – paragraph 11 11. The assessor, with the assistance of the co-assessor, shall take into account the comments of the designated sub-group and
Amendment 390 #
Proposal for a regulation Article 6 – paragraph 12 12. The Coordination Group shall approve the final joint clinical assessment report and summary report, wherever possible by consensus or, where necessary, by a simple majority of Member States.
Amendment 391 #
Proposal for a regulation Article 6 – paragraph 12 12. The Coordination Group shall approve the final joint clinical assessment report and summary report, wherever possible by consensus or, where necessary,
Amendment 392 #
Proposal for a regulation Article 6 – paragraph 12 12. The Coordination Group shall
Amendment 393 #
Proposal for a regulation Article 6 – paragraph 12 12. The Coordination Group shall approve the final joint clinical assessment report and summary report, wherever possible by consensus or, where necessary, by a
Amendment 394 #
Proposal for a regulation Article 6 – paragraph 12 12. The Coordination Group shall approve the final joint clinical assessment report and summary report, wherever possible by consensus or, where necessary, by a simple majority of Member States. Diverging positions and the grounds on which they are based should be recorded in the final report.
Amendment 395 #
Proposal for a regulation Article 6 – paragraph 12 12. The Coordination Group shall approve the final joint clinical assessment report and summary report, wherever
Amendment 396 #
Proposal for a regulation Article 6 – paragraph 12 12. The Coordination Group shall approve the final joint clinical assessment report and summary report, wherever possible by consensus or, where necessary, by
Amendment 397 #
Proposal for a regulation Article 6 – paragraph 12 12. The Coordination Group shall approve the final joint clinical assessment report and summary report, wherever possible by consensus or, where n
Amendment 398 #
Proposal for a regulation Article 6 – paragraph 12 12. The Coordination Group shall approve the final joint clinical assessment report and summary report, wherever possible by consensus or, where necessary, by a
Amendment 399 #
Proposal for a regulation Article 6 – paragraph 12 12. The Coordination Group shall approve the final joint clinical assessment report and summary report, wherever possible by consensus or, where necessary, by
Amendment 400 #
Proposal for a regulation Article 6 – paragraph 13 Amendment 401 #
Proposal for a regulation Article 6 – paragraph 13 Amendment 402 #
Proposal for a regulation Article 6 – paragraph 13 13. The assessor shall ensure the removal of any information of a commercially sensitive nature from the approved joint clinical assessment report and the summary report. The developer shall be consulted on the report before its publication with a period of 20 working days to flag any information it considers confidential and to justify its commercially sensitive nature. In last resort, the assessor and the co-assessor shall decide.
Amendment 403 #
Proposal for a regulation Article 6 – paragraph 14 a (new) 14a. Upon receipt of the approved joint clinical assessment report and summary report, the submitting health technology developer may object in writing to the Coordination Group and the Commission within 7 working days. The developer shall provide detailed grounds for their objections. The Coordination Group shall evaluate the objections within 7 working days and revise the report, as necessary. It shall approve and submit the final joint clinical assessment report, the summary report and an explanatory document detailing how the objections were addressed to the submitting health technology developer and the Commission.
Amendment 404 #
Proposal for a regulation Article 6 – paragraph 14 a (new) 14a. The joint clinical assessment report and the summary report must be ready in not less than 80 days and not more than 210 days, except in justified cases where, owing to clinical necessity, the process needs to be accelerated or delayed.
Amendment 405 #
Proposal for a regulation Article 6 – paragraph 14 a (new) Amendment 406 #
Proposal for a regulation Article 6 – paragraph 14 a (new) 14a. The approval timelines of the clinical assessment report will be set in consultation with the national HTA authorities, in order to avoid further delays to national pricing and reimbursement processes.
source: 623.757
|
History
(these mark the time of scraping, not the official date of the change)
docs/0 |
|
docs/4 |
|
docs/5 |
|
docs/6 |
|
docs/8 |
|
docs/9 |
|
docs/11 |
|
docs/11 |
|
docs/13 |
|
docs/14 |
|
docs/14 |
|
docs/14/docs/0/url |
/oeil/spdoc.do?i=31544&j=0&l=en
|
docs/15 |
|
docs/16 |
|
docs/16 |
|
docs/17 |
|
docs/18 |
|
docs/18 |
|
docs/19 |
|
docs/21 |
|
docs/22 |
|
docs/23 |
|
docs/24 |
|
docs/25 |
|
events/0 |
|
events/11 |
|
events/12 |
|
events/13 |
|
events/15 |
|
events/16 |
|
events/18 |
|
events/18/summary |
|
links/Research document/url |
Old
http://www.europarl.europa.eu/thinktank/en/document.html?reference=EPRS_BRI(2018)614772New
https://www.europarl.europa.eu/thinktank/en/document/EPRS_BRI(2018)614772 |
events/17 |
|
procedure/final |
|
procedure/stage_reached |
Old
Procedure completed, awaiting publication in Official JournalNew
Procedure completed |
docs/19 |
|
docs/25 |
|
events/15 |
|
procedure/stage_reached |
Old
Awaiting Parliament 2nd readingNew
Procedure completed, awaiting publication in Official Journal |
docs/24 |
|
events/14 |
|
events/15 |
|
forecasts |
|
docs/18/summary |
|
forecasts/0/date |
Old
2021-12-14T00:00:00New
2021-12-13T00:00:00 |
docs/19 |
|
docs/18 |
|
events/12 |
|
events/13 |
|
forecasts |
|
docs/17 |
|
docs/16/docs/0 |
|
docs/16 |
|
docs/15 |
|
procedure/dossier_of_the_committee/0 |
ENVI/9/05741
|
procedure/dossier_of_the_committee/0 |
ENVI/8/12220
|
procedure/stage_reached |
Old
Awaiting Council's 1st reading positionNew
Awaiting Parliament 2nd reading |
events/11 |
|
docs/0 |
|
events/0 |
|
events/7 |
|
events/7/docs |
|
events/8 |
|
events/1/body |
EP
|
events/2/body |
EP
|
events/3/body |
EP
|
events/6/body |
EP
|
events/9/body |
EP
|
docs/2/docs/0/url |
https://www.europarl.europa.eu/doceo/document/ENVI-PR-622011_EN.html
|
docs/6/docs/0/url |
https://www.europarl.europa.eu/doceo/document/ENVI-AM-623757_EN.html
|
docs/7/docs/0/url |
https://www.europarl.europa.eu/doceo/document/ENVI-AM-623758_EN.html
|
docs/8/docs/0/url |
https://www.europarl.europa.eu/doceo/document/IMCO-AD-622139_EN.html
|
docs/9/docs/0/url |
https://www.europarl.europa.eu/doceo/document/JURI-AL-627727_EN.html
|
docs/11/docs/0/url |
https://www.europarl.europa.eu/doceo/document/ITRE-AD-620890_EN.html
|
events/4/docs |
|
events/10 |
|
events/11 |
|
docs/0 |
|
events/0 |
|
docs/0 |
|
docs/2 |
|
docs/2/docs/0/url |
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE622.011
|
docs/3 |
|
docs/6 |
|
docs/6/docs/0/url |
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE623.757
|
docs/7 |
|
docs/7 |
|
docs/7/docs/0/url |
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE623.758
|
docs/8 |
|
docs/8 |
|
docs/8/docs/0/url |
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE622.139&secondRef=03
|
docs/9 |
|
docs/9 |
|
docs/9/docs/0/url |
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727
|
docs/10 |
|
docs/11 |
|
docs/11/docs/0/url |
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE620.890&secondRef=03
|
docs/12 |
|
events/0 |
|
events/0 |
|
events/1 |
|
events/1 |
|
events/2 |
|
events/2 |
|
events/3 |
|
events/3 |
|
events/4 |
|
events/4/docs |
|
events/5 |
|
events/6 |
|
events/7 |
|
events/8 |
|
events/8 |
|
events/8/docs |
|
events/9 |
|
committees/0 |
|
committees/0 |
|
committees/1 |
|
committees/1 |
|
committees/2 |
|
committees/2 |
|
committees/2/type |
Old
Committee OpinionNew
Former Committee Opinion |
committees/3 |
|
committees/3 |
|
committees/3/type |
Old
Committee OpinionNew
Former Committee Opinion |
committees/4 |
|
committees/4 |
|
committees/4/type |
Old
Committee OpinionNew
Former Committee Opinion |
committees/5 |
|
committees/5 |
|
committees/5/type |
Old
Committee OpinionNew
Former Committee Opinion |
committees/6 |
|
committees/6 |
|
committees/6/type |
Old
Committee OpinionNew
Former Committee Opinion |
committees/7 |
|
committees/7 |
|
committees/7/type |
Old
Committee OpinionNew
Former Committee Opinion |
committees/8 |
|
committees/8/type |
Old
Committee Legal Basis OpinionNew
Former Committee Legal Basis Opinion |
docs/8/docs/0/url |
Old
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE622.139New
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE622.139&secondRef=03 |
docs/9/docs/0/url |
Old
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727&secondRef=01New
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727 |
docs/11/docs/0/url |
Old
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE620.890New
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE620.890&secondRef=03 |
committees/0 |
|
committees/0 |
|
committees/3 |
|
committees/3 |
|
committees/4 |
|
committees/4 |
|
committees/7 |
|
committees/7 |
|
committees/0 |
|
committees/0 |
|
committees/3 |
|
committees/3 |
|
committees/0 |
|
committees/0 |
|
committees/3 |
|
committees/3 |
|
committees/0 |
|
committees/0 |
|
committees/3 |
|
committees/3 |
|
committees/4 |
|
committees/4 |
|
committees/7 |
|
committees/7 |
|
docs/8/docs/0/url |
Old
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE622.139&secondRef=03New
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE622.139 |
docs/9/docs/0/url |
Old
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727New
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727&secondRef=01 |
docs/11/docs/0/url |
Old
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE620.890&secondRef=03New
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE620.890 |
committees/0 |
|
committees/0 |
|
committees/7/rapporteur/0/mepref |
96761
|
procedure/Modified legal basis |
Rules of Procedure EP 159
|
procedure/Other legal basis |
Rules of Procedure EP 159
|
procedure/stage_reached |
Old
Awaiting Council 1st reading position / budgetary conciliation convocationNew
Awaiting Council's 1st reading position |
docs/9/docs/0/url |
Old
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727&secondRef=01New
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727 |
docs/9/docs/0/url |
Old
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727New
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727&secondRef=01 |
docs/18 |
|
docs/9/docs/0/url |
Old
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727&secondRef=01New
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727 |
docs/9/docs/0/url |
Old
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727New
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727&secondRef=01 |
docs/9/docs/0/url |
Old
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727&secondRef=01New
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727 |
docs/9/docs/0/url |
Old
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727New
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727&secondRef=01 |
docs/9/docs/0/url |
Old
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727&secondRef=01New
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727 |
docs/8/docs/0/url |
Old
http://httsp://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE622.139&secondRef=03New
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE622.139&secondRef=03 |
docs/9/docs/0/url |
Old
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727New
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727&secondRef=01 |
docs/11/docs/0/url |
Old
http://httsp://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE620.890&secondRef=03New
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE620.890&secondRef=03 |
docs/2/docs/0/url |
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE622.011New
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE622.011 |
docs/6/docs/0/url |
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE623.757New
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE623.757 |
docs/7/docs/0/url |
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE623.758New
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE623.758 |
docs/8/docs/0/url |
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE622.139&secondRef=03New
http://httsp://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE622.139&secondRef=03 |
docs/9/docs/0/url |
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727&secondRef=01New
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727 |
docs/11/docs/0/url |
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE620.890&secondRef=03New
http://httsp://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE620.890&secondRef=03 |
events/3/docs/0/url |
Old
http://www.europarl.europa.eu/doceo/document/A-8-2018-0289_EN.htmlNew
https://www.europarl.europa.eu/doceo/document/A-8-2018-0289_EN.html |
events/4/docs/0/url |
Old
http://www.europarl.europa.eu/sides/getDoc.do?secondRef=TOC&language=EN&reference=20181001&type=CRENew
https://www.europarl.europa.eu/sides/getDoc.do?secondRef=TOC&language=EN&reference=20181001&type=CRE |
events/6/docs/0/url |
Old
http://www.europarl.europa.eu/doceo/document/TA-8-2018-0369_EN.htmlNew
https://www.europarl.europa.eu/doceo/document/TA-8-2018-0369_EN.html |
events/8/docs/0/url |
Old
http://www.europarl.europa.eu/sides/getDoc.do?secondRef=TOC&language=EN&reference=20190213&type=CRENew
https://www.europarl.europa.eu/sides/getDoc.do?secondRef=TOC&language=EN&reference=20190213&type=CRE |
events/9/docs/0/url |
Old
http://www.europarl.europa.eu/doceo/document/TA-8-2019-0120_EN.htmlNew
https://www.europarl.europa.eu/doceo/document/TA-8-2019-0120_EN.html |
docs/9/docs/0/url |
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727New
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727&secondRef=01 |
docs/9/docs/0/url |
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727&secondRef=01New
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727 |
docs/9/docs/0/url |
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727New
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727&secondRef=01 |
docs/9/docs/0/url |
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727&secondRef=01New
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727 |
docs/9/docs/0/url |
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727New
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727&secondRef=01 |
docs/9/docs/0/url |
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727&secondRef=01New
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727 |
docs/13/body |
EC
|
events/3/docs/0/url |
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=REPORT&mode=XML&reference=A8-2018-0289&language=ENNew
http://www.europarl.europa.eu/doceo/document/A-8-2018-0289_EN.html |
events/6/docs/0/url |
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=TA&language=EN&reference=P8-TA-2018-0369New
http://www.europarl.europa.eu/doceo/document/TA-8-2018-0369_EN.html |
events/9/docs/0/url |
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=TA&language=EN&reference=P8-TA-2019-0120New
http://www.europarl.europa.eu/doceo/document/TA-8-2019-0120_EN.html |
docs/9/docs/0/url |
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727New
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727&secondRef=01 |
docs/9/docs/0/url |
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727&secondRef=01New
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727 |
events/5 |
|
events/5/date |
Old
2019-02-14T00:00:00New
2018-10-03T00:00:00 |
events/8 |
|
committees/0 |
|
committees/0 |
|
committees/3 |
|
committees/3 |
|
committees/4 |
|
committees/4 |
|
committees/7 |
|
committees/7 |
|
docs/9/docs/0/url |
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727New
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727&secondRef=01 |
docs/9/docs/0/url |
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727&secondRef=01New
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727 |
docs/9/docs/0/url |
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727New
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727&secondRef=01 |
docs/9/docs/0/url |
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727&secondRef=01New
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727 |
docs/9/docs/0/url |
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727New
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727&secondRef=01 |
docs/9/docs/0/url |
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727&secondRef=01New
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727 |
docs/9/docs/0/url |
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727New
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727&secondRef=01 |
docs/9/docs/0/url |
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727&secondRef=01New
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727 |
docs/9/docs/0/url |
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727New
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727&secondRef=01 |
docs/9/docs/0/url |
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727&secondRef=01New
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727 |
docs/9/docs/0/url |
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727New
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727&secondRef=01 |
docs/9/docs/0/url |
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727&secondRef=01New
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727 |
docs/9/docs/0/url |
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727New
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727&secondRef=01 |
docs/9/docs/0/url |
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727&secondRef=01New
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727 |
docs/9/docs/0/url |
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727New
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727&secondRef=01 |
committees/4 |
|
committees/4 |
|
committees/7 |
|
committees/7 |
|
activities |
|
commission |
|
committees/0 |
|
committees/0 |
|
committees/1 |
|
committees/1 |
|
committees/2 |
|
committees/2 |
|
committees/3 |
|
committees/3 |
|
committees/4 |
|
committees/4 |
|
committees/5 |
|
committees/5 |
|
committees/6 |
|
committees/6 |
|
committees/7 |
|
committees/7 |
|
docs |
|
events |
|
other |
|
otherinst |
|
procedure/Mandatory consultation of other institutions |
European Economic and Social Committee European Committee of the Regions
|
procedure/Modified legal basis |
Rules of Procedure EP 159
|
procedure/dossier_of_the_committee |
Old
ENVI/8/12220New
|
procedure/instrument |
Old
RegulationNew
|
procedure/legal_basis/0 |
Rules of Procedure EP 59-p4
|
procedure/other_consulted_institutions |
European Economic and Social Committee European Committee of the Regions
|
procedure/stage_reached |
Old
Awaiting committee decisionNew
Awaiting Council 1st reading position / budgetary conciliation convocation |
procedure/subject |
Old
New
|
procedure/summary |
|
activities/0/commission/0 |
|
activities/0/docs/0/text |
|
activities/1/committees/2/date |
2018-02-26T00:00:00
|
activities/1/committees/2/rapporteur |
|
activities/1/committees/2/shadows |
|
activities/1/committees/4/date |
2018-03-21T00:00:00
|
activities/1/committees/4/rapporteur |
|
activities/1/committees/5/date |
2018-03-15T00:00:00
|
activities/1/committees/5/rapporteur |
|
activities/1/committees/7 |
|
committees/2/date |
2018-02-26T00:00:00
|
committees/2/rapporteur |
|
committees/2/shadows |
|
committees/4/date |
2018-03-21T00:00:00
|
committees/4/rapporteur |
|
committees/5/date |
2018-03-15T00:00:00
|
committees/5/rapporteur |
|
committees/7 |
|
links/Research document |
|
other/0 |
|
activities |
|
committees |
|
links |
|
other |
|
procedure |
|